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ABSTRACT 
 Since their initial conceptualization, polymer-drug conjugate nanocarriers have 
been a mainstay of the drug delivery field. The conjugation of therapeutic agents to 
polymeric carriers offers several critical advantages including improved drug 
solubilization, controlled release, and enhanced safety. Accordingly, polymer-drug 
conjugate nanocarriers are uniquely positioned to remedy some of the limitations of 
conventional small molecule chemotherapeutics, namely their narrow window of 
therapeutic efficacy, rapid clearance, and limited tumor exposure. 
This dissertation describes the design, synthesis, and evaluation of a novel sustained 
release, biodegradable polymeric nanocarrier as a single administration replacement of 
multi-dose paclitaxel (PTX) treatment regimens. The synthesis of poly(1,2-glycerol 
carbonate)-graft-succinic acid-paclitaxel (PGC-PTX) is presented, and its use enables 
high, controlled PTX loadings. Moreover, the polymer backbone is composed of 
biocompatible building blocks—glycerol and carbon dioxide. When formulated as 
nanoparticles (NPs), PGC-PTX NPs exhibit high aqueous PTX concentrations, sub-100 
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nm diameters, narrow dispersity, prolonged storage stability, and sustained and controlled 
PTX release kinetics. In murine models of peritoneal carcinomatosis, in which the clinical 
implementation of multi-dose intraperitoneal (IP) treatment regimens is limited by 
catheter-related complications, PGC-PTX NPs exhibit improved safety at high doses, 
tumor localization, and efficacy even after a single IP injection, with comparable 
therapeutic effect to multi-dose IP PTX treatment regimens.  
The PGC-PTX NP platform is additionally amenable to optimization via 
modulation of nanocarrier properties. Specifically, the dual conjugation and physical 
entrapment of PTX in the NPs harnesses the physicochemical interactions between free 
and conjugated PTX to achieve unprecedented ultra-high drug loadings as well as facile 
control of nanomechanical properties and release kinetics. Optimization of these 
programmable carriers consequently enables the safe delivery of high drug doses as well 
as sustained therapeutic efficacy. In a murine model of peritoneal carcinomatosis, a single 
high dose of dual-loaded PGC-PTX nanocarriers affords significantly improved survival 
compared to weekly, multi-dose PTX treatment.  
Modulation of nanocarrier properties via the incorporation of poly(lactide-co-
glycolide) (PLGA) is additionally explored. Although the integration of PLGA does not 
significantly alter NP physical properties, the polymer blend nanocarriers exhibit improved 
in vitro potency relative to PGC-PTX NPs, warranting the continued evaluation of the 
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 Polymer-drug conjugate therapeutics are pharmacologically active macromolecular 
constructs minimally comprising one or more therapeutic agents covalently bound to a 
polymeric carrier. The conjugation of bioactives to polymers confers numerous valuable 
benefits including enhanced drug solubilization, controlled delivery, increased efficacy, 
and improved pharmacokinetics. Although the first polymer-drug conjugate was reported 
in 1955 by Jatzkewitz, the field of polymer therapeutics was propelled by the seminal work 
of Ringsdorf, Kopecek, and Duncan, among others, in the 1970s1-3. The tangible clinical 
utility of polymer conjugation was realized in 1990 with the first market approval of a 
polymer-protein conjugate, Adagen. Since these pioneering efforts, the field of polymer-
drug conjugates has exhibited remarkable growth. Advances in synthetic polymer 
chemistry and materials engineering are significantly expanding the repertoire of available 
materials, architectures, and functionalities. In particular, responsive and multifunctional 
carriers afford the exciting opportunity to use rational design and precise molecular 
engineering to control and optimize the delivery of therapeutic agents. Integrating the 
present versatility of polymer-drug conjugate design with our growing understanding of 
the complex pathophysiology of various indications will radically transform existing drug 
development efforts as well as current treatment paradigms. 




development of different classes of polymer-drug conjugates, including polymer-protein 
and -small molecule drug conjugates, dendrimers, and polymeric nanoparticles (Figure 
1.1). Central design considerations, including choice of linker chemistry, implementation 
of responsive modalities, and integration of targeting moieties are also presented and 
discussed. We additionally highlight the design and development of sophisticated 
multifunctional systems, which uniquely afford the simultaneous implementation of 
multiple therapeutic and/or imaging modalities in a single macromolecular carrier. Despite 
the tremendous progress achieved in the field, several obstacles currently impede the 
clinical translation of polymer-drug conjugate therapeutics. We therefore provide an 
overview of present translational challenges and discuss future prospects. 
 
1.2 Classes of Polymer-Drug Conjugates 
1.2.1 Polymer-Protein Conjugates 
 The launch of recombinant insulin in 1982 propelled the remarkable upsurge in the 
development of biopharmaceuticals, including peptide and protein therapeutics4, 5. 
However, despite their significant clinical promise, these agents commonly suffer from 
low solubility, poor stability, rapid clearance, and immunogenicity6-8. Pioneering work by 
Abuchowski et al. in 1977 demonstrated the utility of polymer conjugation in ameliorating 
protein immunogenicity, improving solubility, and extending plasma half-life9, 10. The 
conjugation of protein therapeutics with polyethylene glycol (PEG), i.e., PEGylation, has 
since led to the development of several clinically approved polymer-protein conjugates as 




rheumatoid arthritis11. PEG is a highly water-soluble, flexible, uncharged, and 
biocompatible polymer that is widely used as an excipient in the pharmaceutical industry. 
When bound to a protein therapeutic, PEG shields antigenic epitopes via steric repulsion, 
thereby reducing the agent’s immunogenicity6. Additionally, steric repulsion prevents 
degradation by proteolytic enzymes as well as opsonization and subsequent clearance by 
the mononuclear phagocyte system (MPS). The increase in molecular weight and 
hydrodynamic radius conferred by polymer conjugation further reduces plasma clearance 
by renal filtration. The subsequent improvements in protein stability, plasma half-life, and 
immunogenicity reduce the frequency of dosing and improve the overall safety profile of 
the agent.  
The first clinical approval of a PEG-protein conjugate occurred in 1990, soon after 
the start of the biotechnology revolution12. The first approved PEG-protein therapeutic, 
Adagen, is a PEG–adenosine deaminase conjugate used for the treatment of severe 
combined immunodeficiency disease, which is an inherited deficiency of the adenosine 
deaminase enzyme13. The clinical utility and impact of PEGylation has since been well 
established, with a steady stream of PEGylated proteins, including enzymes, cytokines, 
growth factors, and antibodies, entering into clinical evaluation and practice (Table 1.1)12. 
For example, Oncaspar is a PEG-L-asparaginase conjugate approved for the treatment of 
acute lymphoblastic leukemia14. Oncaspar exhibits an extended plasma half-life of 357 
hours compared to 20 hours for the unmodified enzyme. Therefore, the frequency of dosing 
is reduced from 2-3 times per week to a single biweekly dose. The immunogenicity of the 




hypersensitivity reactions to the native enzyme. Interestingly, despite the increased cost 
per dose, a pharmacoeconomic comparison of Oncaspar and unmodified L-asparaginase 
shows that the PEGylated protein is significantly less costly to payers, demonstrating the 
potential for new therapeutic technologies to improve outcomes while reducing costs15. 
More recently, a PEG-epoetin beta conjugate, Mircera, received clinical approval for the 
treatment of renal anemia in patients with chronic kidney disease (CKD). Mircera exhibits 
an extended plasma half-life of 134 hours compared to other erythropoiesis-stimulating 
agents (ESAs) including native epoetin beta, epoetin alpha, and darbepoetin alpha, which 
have plasma half-lives of 9, 7, and 25 hours, respectively16. The extended plasma half-life 
of Mircera compared to other ESAs affords extended dosing intervals and potentially 
reduces costs associated with anemia management in CKD patients by as much as 59%17-
19. 
Protein PEGylation is typically achieved via the post-polymerization modification 
of semitelechelic monomethoxy-PEG (mPEG) to prevent protein crosslinking. Previously, 
the most common reactive groups targeted for coupling were the amino groups of the N-
terminus and lysine residues20. However, due to the prevalence of lysine, first generation 
conjugation approaches lead to uncontrolled, multi-site PEGylation, resulting in 
heterogeneous mixtures of PEG-protein conjugates (i.e., PEGmers). Meanwhile, 
uncontrolled PEGylation at or near binding or catalytic sites results in reduced and varied 
bioactivity among PEGmers7. First generation conjugation approaches additionally suffer 
from protein crosslinking due to the presence of contaminating PEG-diol3, 21. Newer 




methodologies (Figure 1.2)22, 23. Currently, chemical ligation strategies are available for 
efficient and site-specific conjugation at cysteine24-26, tyrosine27-29, tryptophan30, 31, 
histidine32, 33, and arginine34 residues. Methods for the selective modification of the N-
terminus35-37 and C-terminus38-40 have also been reported. Expansion of the ligation 
strategies available for protein PEGylation affords increased molecular control, facilitating 
the rational design of polymer-protein conjugates in which structure and bioactivity are 
retained. In the absence of direct chemical approaches, elegant techniques using enzyme-
mediated ligation as well as genetically engineered expression of unnatural amino acids 
are being utilized for site-specific polymer conjugation. For example, the use of 
transglutaminase enables the selective incorporation of PEG at glutamine residues, which 
are not otherwise chemically accessible41-43. Recently, sortase-specific motifs were 
expressed in therapeutic cytokines and subsequently utilized to achieve sortase-mediated, 
site-specific PEGylation at protein termini, yielding homogenous conjugates with extended 
plasma half-lives and full biological activity44. The site-specific expression of unnatural 
amino acids with orthogonal chemical reactivities provides a previously unrealized 
opportunity to create libraries of PEG-protein conjugates by modulating the precise 
position of the target non-native amino acid on the protein of interest (Figure 1.2a)45, 46. 
This is particularly important for the screening and optimization of PEGylated protein 
therapeutics, as PEGylation at different sites gives rise to unpredicted and significant 
variability in pharmacokinetics and pharmacodynamics46, 47. An alternative approach to the 
post-polymerization modification of semitelechelic polymers (i.e., “grafting to”) is the 




an initiating site incorporated into the target protein (Figure 1.2b)8, 22, 48. In addition to 
affording synthetic precision, this technique provides the advantage of minimized steric 
hindrance, and therefore, improved reaction efficiency. Moreover, synthetic and 
purification steps are simplified, which is a significant advantage for the large-scale 
production of polymer-protein therapeutics. Currently, more versatile approaches are being 
employed including the direct incorporation of reversible addition fragmentation chain 
transfer (RAFT) agents into proteins49, 50, and the introduction of atom transfer radical 
polymerization (ATRP) initiators via genetically encoded unnatural amino acids51 and 
intein-mediated ligation52.  
 Despite its widespread use, a significant limitation of PEG and its subsequent utility 
in therapeutics is its non-biodegradability. Presently, approved PEGylated protein 
therapeutics employ PEGs of ≤40 kDa molecular weight, close to the glomerular filtration 
threshold of approximately 50 kDa53. Although increased molecular weight generally 
affords extended circulation time, concerns regarding the accumulation of non-
biodegradable PEG limit the optimization of polymer molecular weight and resultant 
pharmacokinetics54. Consequently, chemical approaches are being developed to impart 
biodegradability to PEG, for example, via the incorporation of bio-cleavable units in the 
main chain (Figure 1.2c)55, 56. New biodegradable alternatives to PEG are also being 
employed to enhance protein pharmacokinetics, and present an exciting opportunity in the 
development of the next generation of polymer-protein conjugates52, 57-61. Conflicting 
reports on the immunogenicity and antigenicity of PEG have further prompted interest in 




novel zwitterionic and biomimetic alternatives have been described65-68. Notably, a 
heparin-mimicking polymer affords stabilization of a heparin-binding protein—basic 
fibroblast growth factor—which is otherwise unstable, even after PEGylation68. In addition 
to the traditional advantages of polymer conjugation, the ligation of responsive polymers 
affords “smart” conjugates in which protein activity and release can be modulated69-71. 
Additionally, amphiphilic polymer-protein conjugates can be incorporated into 
sophisticated superstructures to alter their pharmacokinetic profile as well as to increase 
functionality via the entrapment and co-delivery of additional active agents72, 73. 
1.2.2 Polymer-Small Molecule Drug Conjugates 
 The first polymer-small molecule drug conjugate was reported over 60 years ago, 
in 1955, by Jatzkewitz, who demonstrated that the conjugation of mescaline, a psychedelic 
alkaloid, to polyvinylpyrrolidone using a dipeptide spacer extends the residence time of the 
bioactive in mice74. In the 1970s, Ringsdorf proposed the concept of a pharmacologically 
active polymeric carrier, which concurrently affords drug solubilization and targeting1. 
Subsequently, work by Kopecek and colleagues in the late 1970s led to the development 
of the first synthetic polymer-small molecule drug conjugate to advance to clinical trials, 
with many others following2. Since their conceptualization, water-soluble polymeric 
carriers of small molecule drugs have been of significant clinical interest. The ligation of 
small molecule bioactives to polymeric carriers offers several critical advantages, including 
improved aqueous solubility, enhanced stability, extended plasma half-life, active 
intracellular delivery, altered biodistribution, and the potential for targeted delivery via the 




control over the release and subsequent activity of the molecule. These advantages are 
particularly pertinent to cytotoxic chemotherapeutics, which often exhibit poor solubility, 
rapid clearance, and limited tumor exposure. Importantly, the efficacy of anticancer agents 
is severely limited by off-target toxicity, prompting the development of approaches which 
afford control of biodistribution and activity. In the 1980s, Matsumura and Maeda reported 
that a polymeric conjugate of the anticancer protein neocarzinostatin preferentially 
accumulates in tumor tissue following intravenous administration75. They proposed that 
the hyperpermeability of tumor vasculature, in combination with impaired lymphatic 
drainage, results in the passive accumulation of macromolecules in tumors, and termed this 
phenomenon “the enhanced permeability and retention (EPR) effect”. Consequently, 
polymer-drug conjugates of small molecule anticancer agents exhibit improved safety and 
efficacy in preclinical animal models, with many advancing to clinical evaluation (Table 
1.2). 
 The first polymer-small molecule drug conjugates to advance to clinical trials 
employed copolymers of N-(2-hydroxypropyl)methacrylamide (HPMA), polyglutamic 
acid, or PEG as carriers of cytotoxic chemotherapeutic agents. PK1, the first clinically 
investigated water-soluble polymer-small molecule drug conjugate, comprises doxorubicin 
bound to an HPMA copolymer via a lysosomally cleavable peptidyl linker3. Due to the 
non-biodegradability of the HPMA copolymer, a size of 30 kDa was chosen to ensure renal 
elimination of the carrier. In preclinical animal models, PK1 exhibits a 15-fold 
improvement in plasma half-life, an enhanced safety profile, and greater antitumor efficacy 




accumulation of drug relative to free doxorubicin. Passive tumor targeting is also observed, 
with 45-250x higher drug concentrations in tumor relative to healthy tissue. Clinically, PK1 
has similarly exhibited extended circulation time as well as an overall improved safety 
profile77. However, tumor accumulation of the conjugate was observed in only a small 
subset of patients while efficacy was marginal. More recently, a four-arm PEG-conjugate 
of irinotecan with a nominal molecular weight of 20 kDa, Onzeald, has rapidly progressed 
to Phase 3 clinical trials. Onzeald employs a cleavable ester linkage to bind one irinotecan 
molecule per PEG arm78. The ester linkage slowly hydrolyzes to release irinotecan, which 
is subsequently metabolized into the active anticancer agent, SN-38. In preclinical animal 
models, Onzeald exhibits an extended circulation half-life and subsequently confers 
sustained SN-38 concentrations in plasma and tumor, with 300x increased total drug 
exposure (AUC). Of note, while tumor Cmax is 6-10x greater after administration of 
Onzeald compared to irinotecan, plasma Cmax is reduced, potentially affording an improved 
therapeutic index. Consequently, administration of Onzeald results in sustained tumor 
suppression and regression for weeks after treatment. In Phase 1 first-in-human studies, 
Onzeald demonstrated similarly improved pharmacokinetics, with SN-38 exhibiting an 
elimination half-life of 50 days compared to 12-47 hours following irinotecan 
administration79. However, in a recent Phase 3 trial, Onzeald did not confer an 
improvement in overall survival compared to a single-agent treatment of physician’s choice 
in patients with advanced breast cancer80. Nonetheless, administration of Onzeald 
demonstrated a survival benefit in a subset of patients with a history of brain or liver 




molecule drug conjugate to date, Movantik, received clinical approval in 2014 for the 
treatment of opioid-induced constipation in patients with chronic pain81. Movantik, a PEG 
conjugate of the opioid antagonist naloxone, exhibits reduced permeability and penetration 
into the central nervous system relative to the small molecule drug. Consequently, 
Movantik significantly improves opioid-related constipation while reducing naloxone’s 
ability to counteract opioid-induced analgesia.  
 Due to their non-biodegradability and subsequent constraints on molecular weight, 
first generation conjugates of PEG and HPMA exhibit suboptimal pharmacokinetics. 
Therefore, current research efforts focus on the evaluation of conjugates employing new 
biodegradable and backbone-degradable water-soluble polymers. For example, backbone-
degradable HPMA polymers are synthesized via the incorporation of enzymatically 
degradable oligopeptides sequences in the main chain82-84. Accordingly, degradable high 
molecular weight HPMA polymer-small molecule drug conjugates demonstrate improved 
pharmacokinetics and pharmacodynamics, while exhibiting eventual renal clearance. New 
water-soluble, biocompatible, and biodegradable polymers, such as polycarbonates, are 
likewise being synthesized and evaluated, expanding the repertoire of polymers available 
for drug conjugation85-88. Additionally, biologically active polymers, such as peptide 
molecular transporters, are being employed as drug carriers due to the added biological 
functionality they afford89. Molecular architecture is also emerging as an important 
modulator of polymer-small molecule drug conjugate in vivo fate and subsequent 
therapeutic efficacy, with circular and branched structures (Figure 1.3a) generally 




93. Importantly, polymer branching affords an alternative approach to the synthesis of high 
molecular weight conjugates, without compromising the drug loading efficiency of di-end-
functional polymers such as PEG. For example, PROTHECAN, a first generation 40 kDa 
PEG conjugate with a camptothecin loading of 1.7 wt%, was administered at doses up to 
4,800 g/m2 to achieve a drug dose of only 82 mg/m2 in Phase 1 clinical evaluation3. In 
addition to polymer molecular weight and architecture, linker chemistry can be modulated 
to achieve an optimized drug release profile, and subsequently, enhanced therapeutic 
efficacy. For example, slow and fast releasing HPMA-dexamethasone polymeric 
constructs are designed via the incorporation of hydrazone and hydrazone benzyl ester 
linkers, respectively94. In an in vivo rat model of arthritis, the slow releasing conjugate 
exhibits sustained anti-inflammatory activity, leading to an improved therapeutic outcome 
compared to the fast releasing formulation. The evaluation of polymer-small molecule drug 
conjugate libraries in which molecular weight, architecture, and linker chemistry are varied 
is a valuable approach for the identification of clinically promising therapeutic candidates, 
and will significantly contribute to our knowledge of the respective macromolecular 
therapeutic design requirements for a variety of indications. 
 While first generation polymer-small molecule drug conjugates enhance the 
pharmacokinetics and pharmacodynamics of previously approved small molecule 
therapeutics, the use of polymeric carriers to facilitate the translation and clinical utility of 
novel agents is a particularly exciting and promising avenue for the next generation of 
polymer therapeutics95-97. For example, HIF-1 inhibitors have significant clinical potential 




toxicity98. However, polymeric conjugates of these agents exhibit significantly improved 
safety and, therefore, enhanced therapeutic potential97. The synthesis of biomimetic 
polymer therapeutics, which incorporate the structural and chemical features of 
therapeutically active molecules, also presents an innovative paradigm in the rational 
design of the next generation of “drug-free” macromolecular therapies. Recently, Kopecek 
and colleagues developed “drug-free” bioactive conjugates of anti-CD20 Fab’ fragments, 
eliminating the adverse side-effects associated with Fc fragment-mediated biological 
events99-102. Due to their multivalency, these conjugates also exhibit increased avidity and, 
therefore, greater apoptosis induction in malignant B cells. 
1.2.3 Dendrimers 
 Dendrimers are unimolecular, highly branched, three-dimensional polymeric 
macromolecules first described by Newkome and Tomalia in 1985103, 104. Repeat branching 
units, or generations, radiating from an initiating core are added stepwise, affording high 
synthetic precision and low dispersity. Importantly, dendrimers exhibit high surface 
functionality, with the number of surface groups increasing exponentially with the addition 
of each generation. Due to their utility in generating synthetically precise libraries of 
monodisperse and tunable nanostructures with high functionality, dendrimers have been 
extensively explored as drug delivery vehicles. Similar to linear polymer drug carriers, 
dendritic carriers of small molecule drugs afford improved aqueous solubility, as well as 
extended circulation time and altered biodistribution in preclinical animal models. 
However, due to their relatively large hydrodynamic radii, dendrimers exhibit reduced 




molecular weight105. Additionally, owing to their high functionality, drugs, imaging, and 
targeting agents are incorporated at high density in dendritic carriers. Recently, the first 
dendrimer-based drug product, VivaGel, received market approval in Australia and the 
European Union for the treatment of bacterial vaginosis. VivaGel is a poly(L-lysine) 
dendrimer-based topical microbicide, in which the macromolecular dendrimer itself is the 
active pharmaceutical agent106. A poly(L-lysine) dendrimer-docetaxel conjugate, DEP 
docetaxel, is also under development by Starpharma, and has recently demonstrated 
enhanced safety, longer plasma half-life, lower peak blood concentrations, and greater 
overall drug exposure relative to conventional docetaxel in a Phase 1 clinical trial (Table 
1.2)107. 
 The most widely studied dendrimers to date are non-biodegradable, cationic amine-
terminated polyamidoamine (PAMAM) dendrimers. However, in addition to being non-
biodegradable, the clinical utility of PAMAM dendrimers is significantly limited by the 
non-specific toxicity and hemolysis attributed to their cationic surface charge108. To 
improve their biocompatibility, the surface charge of cationic dendrimers is minimized via 
surface functionalization109, 110. Additionally, biodegradable and biocompatible 
alternatives, including peptide-, polyurea-, and polyester-based dendrimers, are currently 
being synthesized and evaluated for biomedical applications111-119. While therapeutic 
entities can be physically entrapped within a dendrimer, conjugation affords high drug 
loadings as well as controlled and sustained drug release kinetics109, 120-123. For example, 
the conjugation of fluocinolone acetonide to a PAMAM dendrimer affords sustained drug 




the carrier attenuates retinal degeneration for up to 30 days in a preclinical animal model. 
Interestingly, the release of conjugated active agents buried within dendrimers is 
modulated by varying the number of generations as well as the surface chemistry, 
providing an additional layer of control for the design of optimal drug carriers123.  
 Dendrimers additionally afford modulation and optimization of cellular interactions 
via controlled surface modification. Notably, amine-terminated PAMAM dendrimers 
exhibit pH-dependent ligand exposure, and subsequently, tunable cellular interactions124. 
The extent of cellular interactions of targeted, PEGylated dendritic structures also depends 
on nanoscale surface features, including PEG corona length and targeting ligand density, 
rendering control and optimization of surface features essential for the rational design of 
clinically transformative drug carriers125. Furthermore, owing to their high surface 
functionality, the conjugation of many targeting ligands on a dendrimer enables increased 
avidity, enhancing the utility of targeting moieties which otherwise possess low binding 
affinities. For example, the enhanced avidity of multivalent targeted dendrimers can be 
employed to bind resistant bacteria as well as circulating tumor cells126, 127. The conjugation 
of epitopes to dendritic carriers likewise affords inventive self-adjuvating vaccines128. 
Interestingly, non-targeted dendrimers exhibit transepithelial transport, which can be 
modulated by surface functionalization with PEG129. Therefore, dendritic carriers are 
emerging as useful vehicles for achieving and controlling drug delivery across biological 
barriers. For example, dendrimers traverse the blood-brain barrier and localize in injured 
neurons and microglia upon systemic administration109, 130. Additionally, dendrimer drug 




in the delivery of therapeutic agents113, 131. In cancer nanomedicine, dendritic carriers are 
of particular interest due to their concomitant ability to exhibit passive tumor accumulation 
as well as deep tumor penetration132, 133.  Consequently, dendrimer-drug conjugates are 
incorporated into sophisticated nanoarchitectures to combine the long circulation time and 
increased tumor accumulation of large nanostructures (~100 nm) with the increased tumor 
penetration of smaller dendrimers (~5 nm)133. Similarly, dendrimersomes (Figure 1.3b) 
combine the synthetic precision of dendrimers with the added functionality of unilamellar 
vesicles, which can, for example, carry hydrophilic agents in their aqueous core134.  
 Although most preclinical dendrimer-based therapeutics employ dendrimers as 
macromolecular drug carriers of bioactive agents, dendritic structures with intrinsic 
bioactivity and photoluminescence have been described111, 135, 136. For example, dendritic 
analogues of natural antimicrobial peptides exhibit antimicrobial activity, with the 
translation of VivaGel highlighting the clinical potential of such agents106, 135. Interestingly, 
cationic poly(L-lysine) dendrimers demonstrate inherent anti-angiogenic activity, 
affording comparable tumor growth delay to Avastin136. Utilizing bioactive dendrimers as 
drug carriers affords the realization of novel, multimodal therapies in which the carrier 
contributes to the therapeutic efficacy of the system. 
1.2.4 Polymer Nanoparticles 
 In the late 1970s, Kopf et al. reported the first preparation of a polymeric 
nanoparticulate carrier137. Polymeric nanoparticles, which are colloidal carriers with 
dimensions on the nano-scale, have since been widely employed as drug delivery 




improved delivery of hydrophobic agents as well as extended circulation and altered 
biodistribution of encapsulated therapeutics. However, compared to water-soluble linear 
polymers and dendrimers, colloidal polymeric nanoassemblies exhibit greater architectural 
complexity and afford enhanced tunability via modular design of both core and surface 
components. The most widely investigated polymeric nanoassemblies possess a core-shell 
architecture, in which the hydrophobic polymer core is sequestered and stabilized by a 
hydrophilic corona. Active processing, either precipitation or emulsification, enables the 
synthesis of solid polymer nanoparticles stabilized by a surfactant. Alternatively, the self-
assembly of amphiphilic block copolymers in aqueous media affords the facile synthesis 
of polymeric micelles. Due to their solid nature, polymeric nanoparticle drug carriers offer 
a unique set of advantages, including the sequestration of agents in the hydrophobic 
nanocarrier core, high drug loading capacity, and controlled drug release via diffusion or 
controlled degradation of the polymer matrix. Although physiochemical interactions 
between a drug and its carrier can be employed to physically entrap active agents in 
polymeric nanoparticles, loading capacity is often limited to ≤10 wt%139-141. Additionally, 
these systems suffer from significant burst release, with >50% of the drug being released 
within 24 hours. In contrast, conjugation of active agents to polymeric nanocarriers enables 
incorporation at high and predefined drug loadings, while choice of linker chemistry and 
modulation of core properties afford controlled release kinetics.  
 The first generation of polymeric nanocarriers to advance to clinical trials were 
polymeric micelles of PEG-poly(amino acid) amphiphilic block copolymers developed by 




evaluation in 2001, and is currently in Phase 2 testing. NK911 is a 40 nm micelle of PEG-
b-poly(aspartic acid) copolymer conjugated to doxorubicin through amide bonds. In 
preclinical studies, NK911 exhibited an extended plasma half-life, increased overall drug 
exposure, greater tumor accumulation, and improved efficacy compared to free 
doxorubicin. Similarly, in Phase 1 clinical testing, NK911 was well tolerated and exhibited 
a longer half-life as well as a larger AUC compared to free doxorubicin143. Nonetheless, 
the recommended dosage of NK911 was ultimately similar to that of standard doxorubicin. 
In order to leverage the full therapeutic potential of polymeric nanoparticles, maintaining 
in vivo structural stability is essential144. Concerns regarding the stability of self-assembled 
nanostructures upon dilution in the blood stream have consequently motivated the 
development of core-crosslinked polymeric micelles as well as solid polymer 
nanoparticles. Recently, a biodegradable, core-crosslinked polymeric micelle with 
covalently entrapped docetaxel, CriPec docetaxel, has entered clinical development and is 
expected to complete Phase 1 testing in 2018. The CriPec nanoparticle platform is 
especially promising as it affords tailored design via control of nanocarrier size, drug 
release kinetics, degradation profile, and surface functionality145. In preclinical animal 
models, CriPec docetaxel exhibits improved efficacy, controlled and sustained plasma drug 
levels, enhanced tumor accumulation, and improved safety at high doses relative to the 
clinical formulation of docetaxel. Although several polymeric nanoparticles are in clinical 
development (Table 1.2), none have entered the market to date. 
 One of the most significant challenges presented in the clinical translation of 




conjugation of therapeutic agents to polymeric carriers contributes to this heterogeneity, 
resulting in polydisperse mixtures of polymers with varied drug loadings and sites of 
modification. Presently, new precise synthetic approaches are emerging to enable the 
synthesis of well-defined polymer-drug conjugate nanoassemblies. In particular, novel 
methodologies, such as drug-initiated, living in situ polymerization and living 
polymerization of prodrug monomers, are being developed and employed for the regio- 
and chemo-selective incorporation of actives into synthetically precise polymeric 
nanoparticles at nearly quantitative loading efficiencies146-149. Currently, the most widely 
used hydrophobic polymers in the fabrication of polymeric nanocarriers are biodegradable 
and biocompatible poly(amino acid)s and polyesters. Although widely employed and used 
in FDA-approved devices, hydrophobic polyesters such as polycaprolactone, poly(lactic 
acid), poly(glycolic acid), and poly(lactide-co-glycolide) exhibit limited functionality for 
drug conjugation. Consequently, polyester-based nanocarriers primarily rely on the 
physical entrapment of active agents. However, recent progress in polymer chemistry is 
enabling the synthesis of new biocompatible and biodegradable polymers with high 
functionality150-152. Additionally, advances in genetic engineering afford the biosynthesis 
of polypeptide carriers with precisely defined compositions, molecular weights, and 
polydispersities153-155. The synthesis of novel multifunctional polymer backbones as well 
as the development of new precise synthetic approaches is facilitating the realization of 
polymeric nanocarriers with high and controlled drug loadings146, 149, 156. For example, the 
atom-efficient incorporation of paclitaxel in a polyglycerol carbonate backbone affords 




compatibility of free paclitaxel with the high-density, paclitaxel-conjugate polymer matrix 
facilitates the additional physical entrapment of the free drug and affords previously 
unattainable ultra-high drug loadings >100 wt% (Chapter 3). Importantly, the concurrent 
maximization of drug/material efficiency (i.e., drug loading) and therapeutic efficacy is 
imperative to the successful clinical development of the next generation of polymeric 
nanocarriers as it has the potential to significantly reduce the high costs of production 
associated with the manufacture of complex macromolecular systems, and additionally 
minimizes a patient’s exposure to synthetic carrier material. The inventive development of 
responsive and multifunctional polymers in recent years is also facilitating the 
sophisticated molecular design of smart polymer nanoparticles with a wide-range of added 
functionalities including pH-responsive fluorescence, endosomal membrane 
destabilization, thermosensitive aggregation and solubilization, and triggered pulsatile 
drug release157-160. 
 The rational design of core components, including choice of active agents, drug 
loading, polymer composition, polymer hierarchical structure, and polymer chain length, 
affords fine-tuned control of nanocarrier properties such as release kinetics, mechanical 
stiffness, stability, and core mobility151, 161-165. For example, more compact polymer 
aggregation is achieved via increased drug loading or increased polymer molecular weight, 
resulting in reduced rates of drug release151, 162. Interestingly, the physical entrapment of 
free paclitaxel in a high-density paclitaxel-conjugate nanocarrier affords modulation of 
mechanical stiffness and drug release kinetics, while maintaining sustained release over 




active agents from macromolecular drug carriers is especially promising as it affords long-
term therapeutic efficacy in the treatment of pathologies which otherwise require frequent, 
repeated administrations of conventional drugs151, 166. Control of spatial arrangement and 
hierarchical structure also enables the synthesis of nanoassemblies with increased 
functionality, for example, via the implementation of multiple compartments in a single 
nanocarrier platform (Figure 1.3c)167, 168. Recently reported one-dimensional, non-
spherical micellar carriers (Figure 1.3d) similarly expand the repertoire of architectures 
available for the design of novel polymeric nanomedicines169.   
 The most commonly employed route of administration in the preclinical evaluation 
of polymeric nanoparticles is systemic, intravenous injection. Despite their utility and 
clinical prevalence, alternative routes of administration are seldom employed due to 
challenges in achieving oral bioavailability and crossing mucosal barriers. Nonetheless, 
polymeric nanoparticles are currently being developed for the controlled delivery of 
therapeutic agents across biological membranes166, 170. For example, the oral delivery of a 
polymeric micelle formulation of the angiogenesis inhibitor TNP-470 concomitantly 
affords long-term therapeutic efficacy while minimizing off-target toxicity166. 
Incorporation of the active agent in the nanocarrier core provides protection from the harsh 
acidic environment of the stomach. Meanwhile, the conjugate is absorbed by the intestine 
but does not penetrate the blood-brain barrier, eliminating the neural dose-limiting 





1.3 Stimuli-Responsive Systems 
 Stimuli-responsive, smart drug delivery systems are of widespread interest due to 
their ability to undergo physical and/or chemical changes in response to endogenous 
biological or external triggers171. The triggered response of these carriers is most often 
employed to achieve control over the spatial and temporal release of bioactives, but is also 
being utilized to access more sophisticated functionalities such as modulation of tissue 
penetration and cellular internalization. Linker chemistry primarily provides control of 
drug release, while responsive polymer backbones are being designed to modulate 
physicochemical parameters such as solubility, stability, conformation, and hydrodynamic 
radius.  
1.3.1 Spatiotemporal Control of Drug Release 
 Choice of linker chemistry is of paramount importance in the design of polymer-
drug conjugate therapeutics as it confers spatiotemporal control over the cleavage and 
subsequent release of active agents. Without sufficient linker stability, a conjugated drug 
can exhibit premature release, annulling the advantages of its macromolecular carrier. 
However, insufficient drug release may result in sub-therapeutic drug levels and, 
consequently, suboptimal therapeutic efficacy. Therefore, a sustained drug release profile 
that affords prolonged therapeutic efficacy is highly desirable. Additionally, harnessing the 
chemical and biological distinguishing features of the target indication to trigger site-
specific release is a promising strategy for achieving high local concentrations of active 




been described and utilized for the sustained or triggered release of therapeutic agents 
(Figure 1.4a).  
 Hydrolytic cleavage is frequently employed in sustained release systems and is 
primarily achieved using ester linkages which afford sustained and continuous release for 
periods ranging from days to months122, 151, 162, 172-174. Nonetheless, to achieve precise 
control of the site of drug release, linkers exhibiting selective cleavage in the biochemical 
microenvironment of the disease site are being developed. These linkers combine 
innovation in chemical synthesis and materials design, with the growing understanding of 
the basic biochemical characteristics of the target indication. For example, enzymatically 
cleavable peptide linkers are employed to achieve tumor-specific drug release in the 
presence of pathologically over-expressed enzymes such as matrix metalloproteinases and 
cathepsin B175-178. Acid-responsive linkers are also widely employed, and represent a 
diverse set of chemical bonds including hydrazone, aconityl, and acetal linkages179. 
Consequently, drug release can be triggered, for example, following cellular internalization 
and subsequent trafficking to acidic endosomal and lysosomal compartments180. 
Importantly, these linkers are useful for the selective delivery of anticancer agents in the 
mildly acidic tumor microenvironment113, 139, 155, 161, 181-183. For example, the preclinical 
evaluation of pH-responsive and non-responsive PAMAM dendrimers demonstrates that 
triggered drug release in the tumor microenvironment affords enhanced tumor drug 
concentrations and, consequently, improved overall efficacy181. Specific intracellular drug 
delivery is also achieved using reduction-sensitive linkages, such as disulfide and thioether, 




particularly advantageous for the treatment of indications in which high intracellular drug 
concentrations are required to overcome efflux pump mediated drug resistance89, 187. 
Additionally, systems targeted for specific cell localization must be designed to retain their 
payload prior to cellular internalization in order to harness their targeting capability. 
Specific cellular localization, combined with triggered intracellular release, affords 
optimized drug delivery by concurrently enhancing therapeutic efficacy and minimizing 
systemic toxicity. Notably, the triggered intracellular delivery of valproic acid using 
PAMAM dendrimers, which selectively localize in activated microglia, results in improved 
efficacy, with only 1/10th of the dose necessary to elicit an equivalent therapeutic effect in 
a large animal model of brain injury109. The conjugate additionally prevents the adverse 
cardiovascular side-effects associated with the free drug. Nonetheless, given the 
complexity of macromolecular drug carriers, it is important to note that in addition to linker 
chemistry, many other physicochemical parameters, such as sterics, polymer molecular 
weight, and nanocarrier composition, also impact the rate of drug cleavage and release. 
Therefore, careful evaluation and judicious choice of all system design parameters are 
necessary for the synthesis of programmable macromolecular carriers. 
1.3.2 Responsive Polymers 
 Stimuli-responsive polymeric materials are of significant interest, principally in the 
design of smart drug delivery systems, which uniquely exhibit physicochemical changes 
in response to endogenous or external stimuli (Figure 1.4b). Consequently, these materials 
are utilized to access a wide range of added functionalities and to enhance carrier-mediated 




and release, the incorporation of enzymatically cleavable or trigger responsive domains in 
polymer backbones imparts concomitant control of polymer degradation83, 160. 
Additionally, cellular internalization is controlled, for example, by modulating surface 
charge or ligand accessibility in response to a given stimulus124, 183. Thermally responsive 
polymers, such as poly(N-isopropylacrylamide) and genetically engineered elastin-like 
polypeptides, exhibit temperature-dependent changes in solubility and aggregation. 
Consequently, these polymers are used to externally regulate the activity of a conjugated 
protein or the in vivo localization of the macromolecular therapeutic69, 158. Size switchable 
drug carriers, which exhibit reversible volume changes or irreversible fragmentation into 
smaller polymeric carriers, are also being developed to enable maximization of both plasma 
half-life and target tissue penetration133, 188, 189. In an important study illustrating the 
therapeutic potential of smart polymer therapeutics, size-switchable 80 nm nanoparticles 
were designed to dissociate into <10 nm dendrimer-platinum conjugates in response to 
tumor acidity189. Therefore, while the large nanocarriers extend blood circulation time, 
dissociation into small dendrimer carriers facilitates enhanced tumor penetration. 
Consequently, these nanoparticles exhibit prolonged half-life, significantly enhanced 
tumor drug accumulation, and improved overall efficacy compared to non-responsive 
nanoparticle-platinum and dendrimer-platinum controls.  
 
1.4 Targeted Delivery 
 Polymer therapeutics confer many valuable benefits to conjugated active agents; 




tissue or cellular level. Consequently, Ringsdorf’s vision of an ideal, pharmacologically 
active polymer therapeutic included a homing device that would enable precise tissue or 
cellular localization1. The specific delivery of active agents to target tissues or cells has 
profound implications on the success of a wide range of drug candidates for which off-
target effects are a concern. Accordingly, this strategy is of particular interest in the 
delivery of cytotoxic anticancer agents, which are typically limited by significant off-target 
toxicities. The recent clinical success of antibody-drug conjugates, which combine the 
potency of cytotoxic chemotherapeutics with the selectivity of recombinant monoclonal 
antibodies, highlights the potential of this approach190. Presently, PK2, an HPMA 
copolymer-doxorubicin conjugate bearing galactosamine to target the hepatocyte 
asialoglycoprotein receptor, is the only targeted polymer-drug conjugate to advance to 
clinical trials3, 191. In Phase 1 clinical evaluation, PK2 demonstrated selective hepatic 
delivery in liver cancer patients, with 17% and 3% of the administered dose of doxorubicin 
accumulating in liver and tumor tissue 24 hours after treatment, respectively192. 
Conversely, the analogous non-targeted conjugate, PK1, did not exhibit any significant 
liver accumulation. Additionally, the resultant tumor drug concentrations were calculated 
to be 12-50x greater than doxorubicin concentrations in biopsied liver tumors after 
administration of the free drug, indicating a potential for improved therapeutic efficacy. 
Nonetheless, the clinical development of PK2 was terminated during Phase 2 evaluation in 
2008193. 
 Current active targeting approaches principally exploit the over-expression of 




ligands which bind these receptors. Alternatively, the unique composition of certain tissues 
affords targeting via molecules which possess high binding affinity for the tissue’s 
distinctive biochemical features. Available targeting moieties represent a diverse class of 
molecules including antibodies, carbohydrates, small molecules, peptides, and aptamers194-
196. Notably, high-throughput combinatorial screening of libraries of peptides and aptamers 
is facilitating the identification of ligand-receptor pairs195. The field of macromolecular 
drug delivery has accordingly benefited from advances in target-ligand identification, with 
preclinical polymer therapeutics employing a diverse array of targeting moieties to achieve 
localized drug delivery and enhanced therapeutic efficacy154, 164, 172, 176, 197, 198. For example, 
the incorporation of a cyclic Arg-Gly-Asp (cRGD) targeting peptide in a PEG-
polyglutamic acid polymeric micelle affords significantly increased tumor platinum 
accumulation as well as enhanced overall efficacy compared to oxaliplatin and control 
micelles bearing a non-targeting peptide198. The integration of various functional ligands 
into polymer-drug conjugate molecular constructs is further facilitated by new 
generalizable and facile techniques, such as chemo-enzymatic bio-orthogonal conjugation 
and mussel-inspired nanocarrier surface functionalization154, 173, 199, 200. Importantly, the 
incorporation of epithelium-specific targeting ligands opens new paradigms in the delivery 
of polymer-drug conjugate therapeutics by enabling their translocation across biological 
barriers201-204. For example, receptors on brain capillary endothelial cells, such as the 
nicotine acetylcholine receptor, recognize ligands in circulation and facilitate their transfer 
across the blood-brain barrier. Accordingly, PEGylated liposomes incorporating a peptide 




preclinical animal model201. Following their translocation, additional targeting ligands can 
facilitate the specific delivery of polymer therapeutics to a precise location within the target 
tissue202. 
 In addition to conferring precise tissue or cellular localization, the incorporation of 
targeting moieties in polymer therapeutic platforms affords additional unique advantages 
and functionalities. For example, the multiplicity of surface functional groups in polymeric 
carriers accommodates the integration of multiple targeting ligands and, consequently, 
multivalent binding126, 127, 205. Due to their ability to simultaneously bind multiple surface 
receptors, multivalent molecules exhibit greater binding affinity than their monovalent 
counterparts, enabling the use of ligands that otherwise exhibit low binding affinity for 
their target. For example, vancomycin exhibits weak binding affinity for vancomycin-
resistant bacterial cell wall. However, the multivalent incorporation of vancomycin in a 
dendritic carrier increases the binding avidity by 4-5 orders of magnitude, restoring 
vancomycin’s ability to bind the resistant cell surface126. Additionally, modulation of 
nanocarrier surface features, such as PEG corona length and target ligand density, provides 
fine-tuned control of avidity and cellular interactions125. Similarly, the incorporation of 
targeting moieties in responsive polymeric carriers affords controlled ligand accessibility, 
an example being the triggered occlusion of ligands in collapsed PAMAM dendrimeric 
architectures124. Control of the subcellular localization of polymeric drug carriers is also 
achieved through the incorporation of ligands that target specific intracellular 





1.5 Multifunctional Polymeric Carriers 
 One of the most exciting opportunities in the development of polymer therapeutics 
is the ability to engineer multiple therapeutic functionalities in a single drug delivery 
system. The multiplicity of functional groups available in polymeric carriers allows the 
concomitant incorporation of multiple, distinct active agents, as well as the combination of 
imaging and therapeutic modalities (Figure 1.5). Accordingly, multifunctional polymer 
therapeutics are of significant clinical interest due to the possibility of effectively and non-
invasively detecting, monitoring, and treating disease via a single carrier.  
1.5.1 Combination Therapy 
 Although most preclinical and clinical polymer therapeutics developed to date 
deliver a single active agent, the administration of drug combinations is a promising 
approach for treating diseases in which molecular complexity, heterogeneity, and/or 
resistance impede the efficacy of single-agent therapy208. In particular, combination 
therapy is well-established in cancer treatment, but is also being explored for other 
indications, such as multiple sclerosis and diabetes209, 210. Combinations of active agents 
can maximize therapeutic efficacy by targeting different molecular pathways or acting on 
different cell subpopulations. Additionally, certain drug combinations exhibit 
superadditive efficacy, or synergism211. Interestingly, in vitro studies demonstrate that for 
a given drug combination, certain agent ratios are synergistic while others are 
antagonistic211. However, ensuring that the optimal ratio of drugs is maintained in vivo is 
challenging as most therapeutic agents exhibit differing pharmacokinetics and 




drug incorporation, are uniquely positioned to maintain and deliver predefined ratios of 
drug cocktails to target tissues or cells. Notably, CPX-351, a recently approved liposomal 
formulation of 5:1 cytarabine:daunorubicin, maintains a fixed ratio of the drugs in plasma 
over an extended period of time and significantly improves survival relative to standard 
cytarabine/daunorubicin combination therapy in acute myeloid leukemia patients212, 213. 
 Due to the broad range of chemical functionalities and architectures afforded, 
polymeric carriers can be synthesized with multiple conjugated and/or physically 
entrapped agents, enabling the facile and controlled incorporation of a wide range of 
therapeutics161, 168, 214-217. For example, the self-assembly of amphiphilic camptothecin 
conjugates into nanocapsules allows the concurrent encapsulation of hydrophilic 
doxorubicin salt in the aqueous core168. Additionally, temporal drug release is achieved, 
with the physically entrapped doxorubicin salt exhibiting relatively accelerated release 
kinetics due to its ability to diffuse from the polymeric carrier without the need for active 
cleavage. Similarly, differential release kinetics of a cocktail of conjugated agents can be 
realized via the implementation of multiple, distinct linking chemistries and provides an 
additional layer of control in combination therapy216. Importantly, the utility of single-
carrier combination therapy is highlighted by the ability of these systems to exhibit 
increased synergism as well as enhanced efficacy relative to the analogous combinations 
of free drugs or single-agent carriers161, 214, 215, 218. In addition to the delivery of drug 
combinations, polymeric carriers can also be employed to simultaneously implement 
multiple therapeutic modalities such as chemotherapy, photodynamic therapy (PDT), and 





 The concurrent integration of imaging and therapeutic modalities in theranostic 
polymer carriers allows patient-specific visualization of drug delivery. Consequently, these 
multifunctional therapies provide valuable information on in vivo pharmacokinetics and 
biodistribution, expediting the realization of next-generation, personalized medicines221. 
For example, the incorporation of a radionuclide in PK1 allowed early quantitation of organ 
and tumor uptake via gamma camera imaging in Phase 1 clinical evaluation77. It was 
therefore possible to identify the subset of patients exhibiting preferential tumor 
accumulation of the conjugate. Importantly, the clinical implementation of such systems 
has the potential to enable personalized treatment monitoring and informed treatment 
selection.  
 Today, increasingly sophisticated and smart polymer theranostics are being 
developed and evaluated177, 184, 219, 220. For example, the incorporation of a gadolinium 
complex in a hydrophobic micelle core prevents the exchange of water, reducing the 
magnetic resonance (MR) signal184. However, upon exposure to intracellular reducing 
conditions, release of disulfide-linked camptothecin affords a hydrophobic to hydrophilic 
transition of the nanocarrier polymer matrix. Consequently, an MR signal is activated only 
following drug release. Furthermore, multiple imaging modalities, such as fluorescence, 
MR imaging, photoacoustic imaging, and positron emission tomography, can be 
simultaneously incorporated for increased clinical functionality177, 220. New ultra-sensitive 
and responsive polymeric nanoprobe technologies also present new opportunities in the 




of targeting moieties expands the applications of these nanoreporters to include molecular 
imaging and diagnosis224-226. Notably, the simultaneous integration of therapeutics, 
imaging agents, and targeting ligands provides the clinically transformative capability to 
both “see and treat” disease. For example, the rational design of a fluorescent, cRGD-
linked polymeric nanocarrier affords targeted, image-guided drug delivery219. On-demand 
therapy is achieved via light irradiation, which generates reactive oxygen species for PDT 
as well as doxorubicin cleavage. Interestingly, polymer-drug conjugates additionally 
demonstrate utility in the preparation of multifunctional “super” nanoassemblies that 
combine the functionality of these carriers with inorganic particles227.  
 
1.6 Challenges and Future Outlook 
 Apart from the established and continued clinical success of polymer-protein and 
polymer-peptide conjugates, polymer-drug conjugate therapies have thus far exhibited 
limited translation to clinical practice. In fact, despite their continued clinical evaluation, 
only one polymeric conjugate of a small molecule drug, Movantik, has successfully entered 
the market. Due to their promising preclinical performance, the majority of clinically 
evaluated conjugates of small molecule drugs are carriers of chemotherapeutic agents. 
Although several systems have demonstrated enhanced pharmacokinetics and reduced 
toxicity, improvements in anticancer efficacy have been marginal76, 191. Notably, the 
preclinical efficacy of anticancer polymer therapeutics has been largely attributed to EPR-
mediated tumor accumulation. However, the passive accumulation of macromolecular 




only 6 of 21 patients treated with PK1 in Phase 1 clinical evaluation exhibited verifiable 
tumor uptake via radionuclide imaging77. Consequently, the selection of patients exhibiting 
passive tumor accumulation may be a promising approach to facilitate the translation of 
polymeric conjugates of anticancer agents230.  Notably, a recent clinical study demonstrated 
that high tumor localization of radiolabeled liposomal doxorubicin is correlated with 
improved response rates, progression free survival, and overall survival in patients 
receiving a combination of liposomal doxorubicin and cisplatin231. However, an interesting 
meta-analysis of preclinical EPR-mediated tumor accumulation of drug carriers shows that, 
on average, only 0.7% of the intravenously injected dose reaches the tumor232. 
Accordingly, the authors suggest that, even in preclinical models exhibiting passive 
accumulation of drug carriers, current systems achieve inadequate delivery of 
chemotherapeutics to tumors. However, an analysis of the tumor localization of the 
analogous small molecule agents is not performed, confounding a direct comparison 
between drug carriers and their small molecule counterparts. Nonetheless, approaches to 
increase the passive tumor accumulation of drug carriers are being developed and 
evaluated233. The tumor microenvironment poses additional barriers to carrier-mediated 
drug delivery, such as poor perfusion, prompting the implementation of innovative designs 
to overcome these barriers234. Although increasing local concentrations of active drug is a 
promising approach to improve efficacy and minimize off-target toxicity, it is nonetheless 
important to bear in mind that increased tumor drug concentrations do not invariably 
translate to improved efficacy. For example, PEGylated liposomal doxorubicin (i.e., Doxil) 




myeloma despite demonstrating higher accumulation of drug in patient tumors76, 235, 236. 
However, Doxil successfully mitigates the cardiotoxicity of doxorubicin and enables 
extended dosing intervals. Therefore, target tissue accumulation, efficacy, and enhanced 
safety are among many parameters contributing to the clinical success of drug carriers237. 
 To ensure their elimination, the first clinically evaluated water-soluble conjugates 
of non-biodegradable HPMA possessed molecular weights below the renal cutoff of 50 
kDa191. Accordingly, this limitation in polymer size potentially contributed to insufficient 
improvements in pharmacokinetics and therapeutic outcomes. However, since these early 
clinical trials, advances in polymer chemistry have enabled the synthesis of high molecular 
weight biodegradable and biocompatible polymeric carriers. Additionally, the complex 
biological obstacles a drug carrier encounters upon infusion may limit its ability to exhibit 
enhanced pharmacokinetics and biodistribution. Most notably, cells of the MPS rapidly 
sequester and clear foreign materials from circulation, reducing their half-life and 
bioavailability238. In addition to traditional PEGylation, emerging approaches to minimize 
MPS clearance include the use of “self” peptides as well as red blood cell membrane 
surface coatings238. Furthermore, little evidence validates the extended stability of drug 
carriers in vivo144. In particular, self-assembled structures, such as polymeric micelles, are 
prone to dissociation upon dilution in the blood stream or in the presence of plasma and 
tissue components which can bind the individual amphiphilic polymers. Although the 
macromolecular therapeutic may nonetheless provide a formulation benefit, immediate 
disassembly and drug release minimize the utility of the polymer carrier. Therefore, careful 




carrier stability is maintained in vivo and that the spatiotemporal release of the active agent 
is not compromised. 
 Despite exciting progress in the field of polymer therapeutics, current development 
approaches are largely empirical. However, the diverse and complex challenges presented 
in the clinical translation of polymer therapeutics necessitate a holistic design approach, 
rigorous optimization, and systematic, high-throughput evaluation of libraries of 
conjugates239. In particular, the development of clinically viable drug carriers requires a 
bottom-up design approach in which the active molecule, indication, and even patient 
subset are defined at the outset. Similarly, robust and quantifiable design criteria are 
critical, especially given that preclinical models are poorly predictive of clinical outcomes. 
For example, for a given therapeutic, indication, and patient population, what quantifiable 
modifications in pharmacokinetics and/or biodistribution are necessary to improve patient 
outcomes? While such questions are challenging to address, computational and theoretical 
modeling approaches can be employed to correlate outcomes with concrete design 
parameters. Importantly, systems must maintain their theoretical physicochemical 
characteristics and behavior in vivo. The complexity of macromolecular therapeutics 
presents additional challenges in manufacture such as reproducibility, scalability, and 
cost228. Therefore, the utility of each structural and/or functional component of a polymer 
therapeutic must be carefully evaluated in order to optimize function and minimize 
complexity. 
 Although the clinical translation of polymer-drug conjugate therapeutics has been 




potential to revolutionize existing treatment paradigms and drug development efforts. 
Notably, the clinical development of conjugates of small molecule actives has been largely 
limited to anticancer agents. Meanwhile, the utility of polymer conjugation has been less 
frequently explored in the treatment of other diseases, such as cardiovascular, central 
nervous system, and metabolic indications, presenting a significant opportunity for future 
development. Additionally, given the high attrition rates of therapeutic candidates and the 
resulting “productivity crisis” in the pharmaceutical industry240, polymer carriers are 
uniquely positioned to enable the clinical translation, and/or optimize the clinical 
performance, of new therapeutic agents. Alternatively, the conjugation of approved agents 
to polymeric carriers provides a means to extend patent life and retain market leadership 
for an existing treatment.  
 
1.7 Conclusions  
 Since the first clinical success of polymer-drug conjugates, significant strides have 
been made in the design and development of polymer therapies. Today, an extensive array 
of synthetic methods, compositions, and architectures is available for the rational and 
modular design of effective polymer therapeutics. The increasingly accessible integration 
of sophisticated functionalities is importantly facilitating the development of smart and 
multifunctional next generation drug carriers. Rational design and continued 
multidisciplinary collaboration will facilitate the realization of clinically transformative 







Figure 1.1 Classes of polymer-drug conjugates on the market or in clinical development. 
Water-soluble polymers are employed for the conjugation of (a) protein or peptide 
therapeutics as well as (b) small molecule drugs. (c) Dendrimers are highly branched, three-
dimensional polymeric architectures with high functionality for drug conjugation. (d) 
Polymeric nanoparticles typically possess a core-shell architecture, with a hydrophobic 







Figure 1.2 Emerging approaches in polymer-protein conjugate development. (a) The site-
specific expression of unnatural amino acids with orthogonal reactivities affords tunable 
and precise control of the position of PEG conjugation. (b) Incorporation of a 
polymerization initiation site in the target protein enables site-specific, in situ 
polymerization. (c) Biodegradable high molecular weight PEGs are synthesized via the 
incorporation of bio-cleavable segments in the main chain. Resulting PEG segments of <50 








Figure 1.3 Architectural diversity of polymer therapeutics. (a) Circular and branched 
polymer-drug conjugates exhibit increased circulation times relative to linear polymers of 
similar molecular weight due to their increased hydrodynamic radii. (b) Dendrimersomes 
are unilamellar vesicles formed via the self-assembly of amphiphilic dendrimers. These 
structures maintain the high functionality of the dendrimer components while 
simultaneously enabling the physical entrapment of additional agents in their aqueous core. 
Amphiphilic linear polymers can self-assemble to afford (c) multi-compartment 
nanoparticles with a hydrophobic polymer compartment and an aqueous core, as well as 







Figure 1.4 Stimuli-responsive functionalities. (a) Stimuli-sensitive linking chemistries 
afford spatiotemporal control of drug release. (b) Responsive, smart polymer carriers 






Figure 1.5 Schematic representation of a multifunctional polymer therapeutic. 
Multifunctional polymeric carriers afford the simultaneous incorporation of multiple 
therapeutic and diagnostic functionalities, including combinations of active agents, 





Table 1.1 Polymer-protein and polymer-peptide conjugates in the clinic or in clinical 
development. 













Neocarzinostatin Liver and renal cancer 
Approved in 
Japan (1993) 





PegIntron PEG Interferon α-2b Hepatitis C 
Approved 
(2000) 
Pegasys PEG Interferon α-2a Hepatitis B and hepatitis C 
Approved 
(2002) 











Mircera PEG Epoetin beta 
Anemia associated with 
chronic kidney disease 
Approved 
(2007) 
Cimzia PEG Anti-TNF-α Fab 
Crohn’s disease, rheumatoid 
arthritis, psoriatic arthritis, 
and ankylosing spondylitis 
Approved 
(2008) 
Krystexxa PEG Uricase Chronic gout 
Approved 
(2010) 
Plegridy PEG Interferon β-1a Relapsing multiple sclerosis 
Approved 
(2014) 








Hepatocellular carcinoma Phase 3 
CDP791 PEG Anti-VEGFR2 Fab Non-small cell lung cancer Phase 2 
BCT-100 PEG Arginase 1 
Acute myeloid leukemia and 
hepatocellular carcinoma 
Phase 2 
Pegsiticase PEG Uricase 
Chronic gout and 
hyperuricemia 
Phase 2 
ErepoXen Polysialic acid Erythropoietin 
Anemia associated with 
chronic kidney disease 
Phase 2 




Table 1.2 Polymer, dendrimer, and nanoparticle conjugates of small molecule therapeutics 
in the clinic or in clinical development. 
Name Polymer Drug Indication(s) Status 






Cisplatin Pancreatic cancer Phase 3 
Opaxio Polyglutamic acid Paclitaxel 
Ovarian, peritoneal, and 
fallopian tube cancers 
Phase 3 
Onzeald PEG (4 arm) Irinotecan Breast cancer Phase 3 
CRLX101 
PEG-cyclodextrin that 




esophageal cancer, ovarian, 
tubal, peritoneal, non-small 











Breast and small cell lung 
cancer 
Phase 2 
OsteoDex Dextran Alendronate Metastatic prostate cancer Phase 2 
Somadex Dextran Somatostatin 
Acromegalia, neuroendocrine 
tumors, and palliative 
treatment of castration 










Advanced solid tumors and 




self assembles into 
nanoparticles 




































CHAPTER 2: Synthesis of Poly(1,2-glycerol carbonate)-Paclitaxel Conjugates and 
Their Utility As a Single High-Dose Replacement for Multi-Dose Treatment 
Regimens in Peritoneal Cancer 
 
2.1 Introduction 
 Cancer continues to be one of the leading causes of mortality worldwide241, 242. 
While cytotoxic chemotherapeutics are a mainstay in the treatment of cancer, the 
optimization of dosing schedules remains a challenge due to the relatively low therapeutic 
index of many antineoplastic agents243, 244. In fact, the dosing of an anticancer agent is 
typically determined in a Phase 1 study, in which the end-point is dose-limiting toxicity 
rather than efficacy. Although continuous multi-day infusion improves the therapeutic 
index of several chemotherapeutics, its implementation remains challenging, especially in 
the local treatment of peritoneal cancers244-246. Additionally, control of both drug level and 
duration of treatment is difficult to achieve via current intermittent bolus dosing. Thus, 
alternative delivery strategies, especially those that are safe and facile to implement (i.e., 
single administration), are of significant interest.  
 Nanoparticle (NP) drug delivery systems possess several advantages over 
conventional small molecule chemotherapeutics138, 144, 171, 187, 247-251. Such nanocarriers 
enhance the delivery of hydrophobic agents, and afford controlled and sustained drug 
release, thereby increasing the efficacy of many anticancer agents in preclinical animal 
models. Importantly, NP drug delivery systems afford an opportunity to enhance 




agents—a topic underexplored in the area of nanomedicine. Of note, one of the advantages 
of Albumin-bound (nab-) paclitaxel (PTX) ABI-007 (Abraxane) is the ability to safely 
administer doses 70% greater than the PTX standard of care252. Polymeric NPs, in 
particular, demonstrate significant advantages as a result of their solid nature144, 253. 
However, polymeric carriers with physically entrapped agents suffer from low drug 
loading and significant burst release254. Alternatively, polymer-drug conjugate NPs 
minimize or eliminate the problem of burst release, while additionally providing the ability 
to incorporate drugs at high, predefined loadings with specifically engineered release 
kinetics144, 162, 255. 
 PTX is one of the most widely used chemotherapeutic agents for a variety of solid 
malignancies, including lung, pancreatic, ovarian, breast, and peritoneal mesothelioma. In 
cells, PTX promotes the polymerization and stabilization of microtubules256, 257. Reduced 
microtubule dynamics result in unattached kinetochores, which are protein complexes that 
connect chromatids to spindle microtubules258. Subsequently, unattached kinetochores 
trigger the spindle assembly checkpoint, resulting in mitotic arrest259. However, clinically 
relevant concentrations of PTX do not cause robust mitotic arrest, but induce multipolar 
spindle formation and, consequently, chromosome missegregation257, 260. Cell death occurs 
in a portion of the aneuploid progeny due to the loss of essential chromosomes. Therefore, 
cell death increases with increased duration of exposure to PTX260. The rational design of 
sustained release PTX drug carriers has the potential to facilitate the clinical 
implementation of prolonged drug exposure. 




index, poor solubility, rapid systemic clearance, and limited tumor exposure261-263. As a 
result of its poor aqueous solubility (0.3 μg/mL), PTX is commonly delivered in a 
Cremophor EL/ethanol (1:1 v/v; C/E) excipient, which is known to cause adverse side-
effects and severe hypersensitivity reactions264, 265. Thus, alternative delivery methods are 
of keen interest. Currently under clinical investigation, a water-soluble macromolecular 
poly(L-glutamic acid)-PTX conjugate (PTX poliglumex) increases PTX solubilization (9 
mg/mL) while exhibiting an improved safety profile and enhanced tumor exposure 
compared to PTX-C/E266. Previously, polymer-PTX conjugate NP delivery systems have 
demonstrated high loading capacities (5-65 wt%), improved PTX aqueous concentrations, 
and controlled and sustained PTX release kinetics for up to 10 days155, 156, 162, 185, 255, 267-269. 
However, systems that deliver PTX over prolonged periods of time are lacking. 
 Motivated by these findings, we herein report the first example of a nanocarrier in 
which PTX is incorporated at high, controlled loadings of up to 74 wt%, and in which PTX 
concentrations are improved by >50,000 fold (>15 mg/mL) compared to PTX solubility in 
aqueous solution. Reducing carrier material and maximizing drug content (i.e. optimizing 
drug/material efficiency) departs from the majority of PTX drug carriers which typically 
achieve <10 wt% drug loading, and therefore require the administration of large amounts 
of carrier material to achieve a given dose. Moreover, we use poly(1,2-glycerol carbonate) 
(PGC) as the novel polymer scaffold for PTX attachment as the PGC backbone is readily 
degradable and biocompatible, consisting of only glycerol and carbon dioxide150, 152. For 
this reason, polymers based on glycerol are of significant interest for drug delivery, tissue 




primary hydroxy provides a site for PTX conjugation via a succinic acid linker in order to 
give poly(1,2-glycercol carbonate)-graft-succinic acid-paclitaxel (PGC-PTX). We 
demonstrate that PGC-PTX NPs possess sub-100 nm diameters, narrow dispersity, high 
storage stability, sustained and controlled release kinetics, tunable in vitro potency, 
improved in vivo safety at high doses, in vivo intraperitoneal (IP) tumor localization, and 
in vivo efficacy even after a single IP injection. 
 
2.2 Results and Discussion 
2.2.1 Synthesis of PGC-PTX Conjugates 
PGC is synthesized via the alternating copolymerization of epoxide and carbon 
dioxide, followed by high pressure hydrogenolysis to remove the benzyl group, as 
previously described (Figure 2.1)150. This metal catalyzed copolymerization reaction is 
versatile, efficient, and amenable to a large number of epoxide monomers274-276. PGC is 
then treated with succinic anhydride and 4-dimethylaminopyridine (DMAP) to give 
poly(1,2-glycerol carbonate)-graft-succinic acid (PGC-g-SA). Standard coupling 
chemistry using N,N'-dicyclohexylcarbodiimide (DCC) and DMAP with PTX affords 
PGC-PTX with high PTX loadings of up to 70 mol%, or 74 wt%. PTX is linked to the 
polymer backbone via hydrolysable ester linkages. PTX incorporation in molar ratio is 
determined via 1H NMR by integrating the peaks that correspond to the methine proton on 
the polymer backbone and the C2’ proton on the PTX side chain. To elucidate the site of 
PTX functionalization, PTX and SA were coupled using DMAP, and the PTX-SA 




that PTX binds SA at its C2’-OH as indicated by the downfield chemical shift of the CH 
proton on C2’ from 4.79 to 5.51 ppm (Figure 2.2). Conjugating PTX at the C2’-OH, which 
is critical for its activity277, 278, confers control over the biological activity of the conjugate 
by necessitating the additional cleavage of PTX into its active form. To study the effect of 
PTX loading on NP behavior, we focus our evaluation on PGC-PTX with 34, 39, and 43 
mol% PTX incorporation (i.e., 34, 39, and 43% PGC-PTX; 58, 61, and 64 wt% PTX 
respectively) as these polymers are reproducibly synthesized with high PTX incorporation 
efficiencies of >80%, and form monodisperse NPs of equal size. Conversely, PGC-PTX 
NPs with 70 mol% (74 wt%) PTX loading are a polydisperse particle population with NPs 
between 10-90 nm (Figure 2.3). By size exclusion chromatography, the PGC-PTX 
constructs used are 9-13 kDa, with polydispersity indices (PDIs) between 1.3 and 1.6 
(Table 2.1).  
2.2.2 Formulation and Characterization of PGC-PTX Nanoparticles 
 It has been previously demonstrated that sub-100 nm particles exhibit effective 
tumor tissue penetration and retention, while sub-50 nm NPs exhibit poor tumor 
retention187, 279, 280. Therefore, a diameter of 50-100 nm was targeted for the PGC-PTX 
nanocarriers. PGC-PTX NPs were prepared using a miniemulsion synthesis procedure in 
which the surfactant, sodium dodecyl sulfate (SDS), was dissolved in phosphate buffer and 
added to a polymer-dichloromethane solution at a 1:5 surfactant:polymer mass ratio 
(Figure 2.4). The mixture was then emulsified under an argon blanket via ultrasonication, 
and the colloid was purified by dialysis. Dynamic light scattering (DLS) and scanning 




(Figure 2.5a,b). PGC-PTX NP size, PDI, and zeta potential (Figure 2.5a,c,d) do not vary 
with PTX loading. However, drug-free NPs composed of poly(benzyl 1,2-glycerol 
carbonate) (PGC-Bn), the PGC polymer prior to deprotection, exhibit slightly smaller 
diameters (63.7 ± 7.6 nm) and greater dispersity (0.126 ± 0.043). The 34, 39, and 43% 
PGC-PTX NPs possess average diameters of 77.9 ± 9.8 nm, 77.5 ± 5.2 nm, and 82.9 ± 4.8 
nm, and PDIs of 0.078 ± 0.034, 0.080 ± 0.028, and 0.080 ± 0.035, respectively. All NPs 
exhibit similar zeta potentials between -43 and -51 mV due to the negative charge of the 
SDS surface coating. Using current formulation parameters, NP solutions with markedly 
high PTX concentrations >15 mg/mL are prepared, compared to PTX aqueous solubility 
of 0.3 μg/mL281. The high concentrations of PTX achieved using PGC-PTX NPs thus 
eliminate the need for additional solubilizing agents such as C/E, while simultaneously 
reducing carrier material due to high PTX incorporation. 
2.2.3 Nanocarrier Storage Stability 
 Among the challenges impeding the translation of nanomedicines into clinical 
practice are batch-to-batch variation, high dispersity, and poor storage stability282. Having 
demonstrated that the PGC-PTX NP formulation is robust and reproducible, and that PGC-
PTX NPs exhibit narrow dispersities, we next evaluated NP storage stability. The 39% 
PGC-PTX NPs were used for analysis as a representative population, as this formulation 
has the median drug loading among the NPs evaluated. The NPs were stored in solution at 
4°C, or lyophilized and stored at -20°C, without the addition of any stabilizing agents. At 
later time-points, lyophilized NPs were resuspended in phosphate buffer and both sets of 




performance liquid chromatography (HPLC), respectively. Over the course of 180 days, 
PGC-PTX NPs maintain a stable diameter of 77-88 nm (Figure 2.6a), and 
free/unconjugated PTX content remains constant at 1-2% of total PTX loading (Figure 
2.6b). Additionally, resuspended NPs do not differ in size or free PTX content from NPs 
stored in solution. SEM micrographs confirm the presence of stable NPs after 90 and 180 
days of storage (Figure 2.6c-f). Taken together, these results demonstrate that PGC-PTX 
NP physicochemical characteristics are not altered under storage conditions for up to 6 
months.  
2.2.4 Drug Release Kinetics 
 To characterize PTX release kinetics as well as the effect of drug loading, 34% and 
43% PGC-PTX NPs were incubated in pH 7.4 phosphate buffer for 70 days at 37°C 
(Figure 2.7). At given time-points, samples were withdrawn from the release media and 
free PTX content was determined via liquid chromatography–mass spectrometry (LC-MS). 
At early time-points (<10 days), PTX release is slightly accelerated in 34% PGC-PTX NPs 
compared to 43% PGC-PTX NPs (Figure 2.7a). At later time-points (>10 days), PTX 
cumulative release is comparable for both formulations (Figure 2.7b). An initial burst 
release is not observed, consistent with release being dependent on both diffusion and 
cleavage of the drug from the polymer backbone. Furthermore, PGC-PTX NPs exhibit 
controlled and sustained drug release kinetics, with 70% and 63% cumulative PTX release 




2.2.5 In Vitro Efficacy 
 In vitro NP cytotoxicity was evaluated after 5 days of treatment in several human 
cancer cell lines:  MSTO-211H mesothelioma cancer cells (Figure 2.8a), A549 lung cancer 
cells (Figure 2.8b), PANC-1 pancreatic cancer cells (Figure 2.8c), and MDA-MB-231 
breast cancer cells (Figure 2.8d). By conjugating PTX to SA at the C2’-OH position 
critical for PTX activity, we reduce the in vitro potency of PTX-SA-C/E relative to PTX-
C/E by requiring the additional cleavage of PTX into its active form. Similarly, due to the 
continuous and sustained release of PTX from the NP formulations, PGC-PTX NPs exhibit 
lower in vitro potency compared to PTX-C/E (Figure 2.8 & Table 2.2). A robust 
correlation between the 50% inhibitory concentration (IC50) and drug content suggests that 
PTX release rates decrease as polymer drug content is increased. This result is in agreement 
with the measured release kinetics, which indicate that at early time-points (<10 days), 
drug release is slightly accelerated in 34% PGC-PTX NPs relative to 43% PGC-PTX NPs. 
Due to the hydrophobic nature of PTX itself, PGC-PTX NPs with higher PTX loadings 
may exhibit reduced cleavage and release rates owing to less water penetration into the 
polymer core. Additionally, the increase in molecular weight resulting from higher drug 
incorporation may result in more compact polymer aggregation in the NP core, further 
contributing to reduced PTX release. These findings are consistent with those reported by 
others investigating PTX conjugate polymeric nanoassemblies156, 162, 185, 269. Cells treated 
with drug-free PGC-Bn NPs at equivalent PGC backbone concentrations to 34% PGC-
PTX NPs exhibit minimal cell death. However, the reduction in cell viability at high 




(Figure 2.9). Nonetheless, the maximum concentration of SDS used in the treatment of 
cells in vitro is 1.8 μg/mL, which is below the range of previously reported IC50 values (43-
127 μg/mL)283-285.  
2.2.6 Cellular Internalization 
 To evaluate NP cellular internalization, a fluorescent rhodamine-labeled PGC-PTX 
polymer (PGC-PTX-Rho; 10 mol% Rho, 40 mol% PTX) was synthesized by first reacting 
PGC with rhodamine B isothiocyanate and proceeding with the reaction as previously 
described to conjugate SA and PTX. PGC-PTX-Rho NPs are formulated in the same 
manner as PGC-PTX NPs and are physically similar, with a diameter of 78.8 ± 8.0 nm, a 
PDI of 0.101 ± 0.059, and a zeta potential of -43 ± 8 mV. The maximum dose of PGC-
PTX-Rho NPs that can be administered without inducing cell death was determined by 
evaluating MSTO-211H cell viability 24 hours after treatment with 40% PGC-PTX NPs. 
Given that cell viability exceeds 95% at PTX doses ≤100 ng/mL (Figure 2.10), MSTO-
211H cells were treated with PGC-PTX-Rho NPs at a dose of 100 ng/mL PTX, and cellular 
internalization kinetics were assessed via flow cytometry at various time-points after 
treatment (Figure 2.11a,b). The increase in fluorescence intensity over time indicates an 
increase in the portion of the cell population which internalized NPs (Figure 2.11a). To 
quantitate internalization, positive cells were defined as cells which exhibit higher 
fluorescence than 99% of the control/untreated population (Figure 2.11b). PGC-PTX Rho 
NP internalization occurs rapidly, with >75% of the cell population taking up NPs after 4 
hours of treatment, and nearly all cells exhibiting NP internalization following 24 hours of 




treatment via confocal microscopy (Figure 2.11c). Further studies will be needed to 
elucidate the intracellular localization of NPs. These results are in agreement with previous 
studies reporting the internalization of negatively charged NPs286-289. 
2.2.7 In Vivo Safety 
Since PGC-PTX NPs contain a substantial quantity of PTX but release their 
payload gradually and continuously, we hypothesized that PGC-PTX NPs can be safely 
administered at significantly higher PTX doses than standard PTX-C/E. For reference, the 
maximum tolerated dose (MTD) of PTX-C/E in mice by IP administration is reported 
between 13-50 mg/kg, while the median lethal dose (LD50) is 128 mg/kg
290-293. To test this 
hypothesis, an approved pilot trial was constructed with IACUC guidance, and healthy 
mice were given 34% PGC-PTX NPs via a single IP injection at a dose of 140 mg/kg PTX. 
The 34% PGC-PTX NP formulation was chosen for in vivo evaluation given its superior 
in vitro efficacy. After treatment with 34% PGC-PTX NPs, mice do not exhibit any signs 
of acute or chronic toxicity and maintain healthy body weight (Figure 2.12). All of the 
mice were euthanized 120 days after treatment, and tissue was harvested for histological 
analysis to evaluate organ toxicity. Histological evaluation of major organs confirms that 
the treatment is well tolerated compared to untreated controls (Figure 2.13). 
2.2.8 Peritoneal Localization and Antitumor Efficacy 
 Encouraged by these results, we evaluated the efficacy of PGC-PTX NPs as a single 
dose in murine models of peritoneal mesothelioma. Mortality in patients with peritoneal 




only 4-12 months post-diagnosis286, 294. Although long-term regional chemotherapy has 
demonstrated improved outcomes in patients with peritoneal carcinomatosis, its 
implementation is limited by catheter-related toxicities and intolerance245, 246. Thus, the 
optimization of long-term IP chemotherapeutic dosing continues to be of clinical interest. 
We hypothesized that a single, high-dose PGC-PTX NP IP injection will leverage the 
utility of the IP route of administration, while exhibiting equivalent efficacy to a multi-
dose PTX treatment regimen due to its sustained release profile.  
First, to determine NP distribution within the peritoneal cavity, mice received an IP 
injection of either PGC-PTX-Rho NPs or rhodamine in saline three weeks after IP MSTO-
211H tumor inoculation. Three days after injection, animals were euthanized, and the 
peritoneum was assessed under ambient and ultraviolet light. By gross inspection, NPs are 
visualized primarily in areas of tumor, suggesting that PGC-PTX NPs preferentially 
localize to IP tumors following local administration (Figure 2.14). This observation is 
consistent with previous reports on the localization of negatively charged NPs to peritoneal 
tumors following IP administration, and may be attributed to the increased metabolic 
activity and more rapid NP internalization of tumor cells compared to healthy cells286, 294-
296. Quantitative and mechanistic studies exploring this phenomenon are underway, 
including the evaluation of the distribution and localization of fluorescently-labeled, non-
drug loaded PGC NPs.  
 We next evaluated the efficacy of PGC-PTX NPs in preventing the establishment 
of mesothelioma locally in the peritoneum. Immediately following IP tumor inoculation 




several treatments via separate IP injection. Treatment groups included a single dose of 
140 mg/kg PTX as 34% PGC-PTX NPs, PGC-Bn NPs (polymer backbone control), 20 
mg/kg PTX-C/E (single PTX dose control), 7x 20 mg/kg daily PTX-C/E (total dose 
control), and 7x 20 mg/kg weekly PTX-C/E (total dose control). Given the known lethality 
of a bolus dose of 140 mg/kg PTX-C/E, this positive control could not be justified, and 
therefore, equivalent PTX dose comparisons were achieved with seven injections of 20 
mg/kg PTX-C/E at daily or weekly dosing intervals. Nonetheless, animals that received 7x 
daily doses of 20 mg/kg PTX-C/E exhibit a 63% acute mortality rate due to PTX-C/E 
toxicity (Figure 2.15a). Conversely, when the equivalent PTX-C/E dose is administered 
over seven weeks, acute toxicity is decreased and animals exhibit comparable survival to 
those receiving a single dose of 140 mg/kg PTX via PGC-PTX NPs (median survivals of 
76 and 86.5 days, respectively; p=0.77). Similarly, at 4 and 6 weeks after tumor 
inoculation, PGC-PTX NP treated animals exhibit comparable tumor burden to animals 
treated with a weekly PTX-C/E multi-dose regimen (Figure 2.15b). Therefore, a single 
high dose of PTX can be safely administered via PGC-PTX NPs without the risk of C/E 
hypersensitivity or other toxicities, and with comparable efficacy to PTX-C/E administered 
as a multi-dose regimen over the course of weeks. 
 To determine whether these findings are replicated in an established model of 
peritoneal mesothelioma, animals were treated one week after tumor inoculation with 
either saline, PGC-Bn NPs (polymer backbone control), or 140 mg/kg PTX administered 
as a single dose of 34% PGC-PTX NPs or as 7x 20 mg/kg weekly PTX-C/E (total dose 




weekly PTX-C/E exhibit similar tumor burden at 4 and 6 weeks after tumor inoculation, 
and overall survival is comparable between PGC-PTX NP and 7x 20 mg/kg weekly PTX-
C/E groups (median survivals of 55 and 65 days, respectively; p=0.80) (Figure 2.16). Due 
to their improved safety profile and sustained PTX release kinetics, PGC-PTX NPs can 




 The conjugation of small molecule anticancer agents to polymeric carriers is a 
promising approach for overcoming the clinical limitations of cytotoxic 
chemotherapeutics. The progression of PTX poliglumex into clinical evaluation highlights 
the potential of this approach to improve patient outcomes. Nonetheless, several key 
features distinguish PGC-PTX NPs from PTX poliglumex. First, PGC-PTX NPs are a 
colloidal drug delivery system, whereas PTX poliglumex is a linear, water-soluble 
polymer-drug conjugate. The formulation of the hydrophobic PGC-PTX polymer into 
colloidal carriers affords high drug loadings of up to 74 wt%. Since PTX poliglumex relies 
on the improved aqueous solubility afforded by the poly-L-glutamic acid backbone, PTX 
loading is limited to 37 wt%266. Additionally, the hydrolytic release of PTX from PTX 
poliglumex occurs at a rate of approximately 12% per day, with most of the drug being 
released within 8 days297. On the contrary, PGC-PTX nanocarriers exhibit controlled and 
sustained drug release over an extended period of 70 days, with <15% of the drug being 




drug and the carrier, the significant difference in release kinetics is likely due to the 
sequestration of PTX within the hydrophobic core of the PGC-PTX NP, which is not 
achieved in the water-soluble PTX poliglumex. The extended release behavior of PGC-
PTX NPs affords their utility as a single, high-dose replacement for multi-dose PTX 
treatment regimens, especially for the treatment of peritoneal cancers, in which the 
implementation of local, multi-dose treatment regimens is challenging. While a previously 
published report illustrates the utility of single, high-dose PTX poliglumex in the local 
treatment of peritoneal cancers relative to multi-dose PTX regimens, PTX-treated animals 
receive significantly lower total drug (15-60 mg/kg PTX given over 3 administrations) 
compared to animals receiving PTX poliglumex (140-200 mg/kg PTX equivalent), 
confounding a direct comparison between the two treatment groups298. 
 In summary, our work presents the rational design of a biodegradable polymeric 
nanocarrier in which PTX is incorporated at high, controlled loadings of up to 74 wt% and 
in which PTX aqueous concentrations exceed 15 mg/mL. Importantly, PGC presents a 
generalizable platform for the controlled conjugation and delivery of other therapeutic or 
imaging agents. The PGC-PTX NP formulation is robust, producing monodisperse sub-
100 nm NPs with long-term storage stability and sustained PTX release kinetics. Due to 
the controlled and sustained release of PTX, PGC-PTX NPs are safely administered at 
doses exceeding the LD50 of PTX-C/E. In vivo, PGC-PTX NPs preferentially accumulate 
in IP tumors after local administration, similar to other negatively charged NPs295. 
Furthermore, a single dose of PGC-PTX NPs exhibits an equivalent oncologic effect to 




patient compliance, reducing costs associated with visits, and eliminating the use of C/E 
and its related toxicities. Notably, PGC-PTX NPs present a unique drug delivery system 
for the improvement and optimization of chemotherapeutic dosing regimens by enabling 
the facile implementation of a high dose, sustained release treatment platform. 
 
2.4 Materials and Methods 
2.4.1 General Information 
 All manipulations involving air- and water-sensitive compounds were carried out 
in a glovebox. Benzyl glycidyl ether was refluxed over CaH2, and fractionally distilled 
under nitrogen atmosphere prior to use. Carbon dioxide (99.995%, research grade) was 
purchased from Airgas (Dorchester, MA) and used as received. Pd/C (10%) (wetted with 
ca. 50% water) were purchased from Strem Chemicals (Newburyport, MA) and used as 
received. 1H and 13C NMR spectra were recorded on a Varian 500 MHz type (1H, 500MHz; 
13C, 125 MHz) spectrometer (Varian, Inc.; Palo Alto, CA). Their peak frequencies were 
referenced against the solvent, chloroform-d at δ 7.24 for 1H NMR and δ 77.23 ppm for 
13C NMR; and dimethyl sulfoxide-(DMSO-)d6 at δ 2.50 for 1H NMR and δ 39.52 for 13C 
NMR. Molecular weights were determined via size exclusion chromatography calibrated 
against polystyrene standards using tetrahydrofuran (THF) as the eluent at a flow rate of 
1.0 mL/min through a Styragel HR 4E 7.8 x 300 mm THF column (Waters Corporation; 





2.4.2 Synthesis of PGC-g-SA 
 Poly(1,2-glycerol carbonate) (PGC) was synthesized via the alternating 
copolymerization of epoxide and CO2 followed by high pressure hydrogenolysis to remove 
the benzyl group, as previously described150. PGC-PTX conjugate was synthesized by first 
reacting PGC with succinic anhydride to provide poly(1,2-glycerol carbonate)-graft-
succinic acid (PGC-g-SA), which possesses a carboxylic acid on each repeating unit. PGC 
(100 mg, 0.85 mmol, 1.0 eq), succinic anhydride (93 mg, 0.93 mmol, 1.1 eq.), and 4-
dimethylaminopyridine (DMAP) (5.2 mg, 0.042 mmol, 0.05 eq.) were added into a 5 mL 
round bottom flask. Dimethylformamide (DMF; 1 mL) was then added to dissolve the 
solid, and the reaction was stirred at room temperature overnight. The reaction mixture was 
then added dropwise into diethyl ether. After centrifugation, the upper layer was decanted 
and the solid was re-dissolved with an ethyl acetate/methanol mixture (3:2). The solution 
was then added dropwise into diethyl ether for a second precipitation, and the mixture was 
centrifuged again to collect the polymer. The isolated polymer was dried under vacuum 
overnight, and the polymer was isolated as a white foam. 1H NMR (500 MHz, DMSO-d6, 
ppm): δ 5.02-5.23 (br, 1H), 4.11-4.46 (br, 4H), 2.38-2.60 (br, 4H); 13C NMR (125 MHz, 
DMSO-d6, ppm): δ 166.0, 153.6, 134.8, 128.8, 128.4, 73.5, 68.0, 66.2, 53.7 (Figure 2.17). 
2.4.3 Synthesis of PTX-SA 
 PTX (100 mg, 0.117 mmol, 1.0 eq.), succinic anhydride (11.1 mg, 0.111 mmol, 
1.05 eq.), and DMAP (0.71 mg, 0.0059 mmol, 0.05 eq.) were added into a 5 mL round 
bottom flask. DMF (1 mL) was added to dissolve the solid, and the reaction was stirred at 




yield: 95 mg, 85%. 1H NMR analysis revealed that the PTX C2’-OH is the only site that is 
active under the reaction conditions described (Figure 2.2). 1H NMR (500 MHz, 
chloroform-d, ppm): δ 1.13 (s, 3H, (C-16)-CH3), 1.25-1.40 (s, 3H, (C-17)-CH3), 1.50-1.70 
(m, 3H, (C-19)-CH3), 1.82-1.95 (m, 5H, (C-6)-CH, 1-OH and (C-18)-CH3), 2.15 (m, 1H, 
(C-14)-CH), 2.23 (s, 3H, 10-OAc), 2.34-2.62 (m, 10H, 4-OAc, (C-6)-CH, (C-14)-CH, 7-
OH, HOOCCH2CH2CO-), 3.81 (d, 1H, (C-3)-CH), 4.20 (d, 1H, (C-20)-CH), 4.31 (d, 1H, 
(C-20)-CH), 4.46 (m, 1H, (C-7)-CH), 4.94 (dd, 1H, (C-5)-CH), 5.51 (d, 1H, (C-2’)-CH), 
5.68 (d, 1H, (C-2)-CH), 5.95 (dd, 1H, (C-3’)-CH), 6.23-6.29 (m, 2H, (C-10)-CH and (C-
13)-CH), 6.85 (d, 1H, 3’-NH), 7.34-7.64 (m, 11H, PhH), 7.73 (d, 2H, PhH), 8.14 (d, 2H, 
PhH); 13C NMR (125 MHz, chloroform-d, ppm): δ 9.6, 14.9, 24.2, 28.4, 35.6, 43.2, 45.6, 
51.1, 52.8, 58.5, 71.8, 72.2, 73.9, 75.1, 75.6, 76.5, 79.2, 81.1, 84.5, 126.5, 127.1, 128.5, 
128.8, 129.1, 129.2, 130.3, 132.1, 132.8, 133.7, 137.0, 142.8, 167.1, 168.1, 169.8, 171.3, 
172.5, 175.5, 203.9. 
2.4.4 Synthesis of PGC-PTX 
 PGC-g-SA was conjugated with PTX under standard coupling conditions to afford 
PGC-g-SA-PTX conjugate (PGC-PTX). As an example, to synthesize PGC-PTX with 34 
mol% PTX loading, PGC-g-SA (100 mg, 0.459 mmol, 1.0 eq.), PTX (157 mg, 0.183 mmol, 
0.4 eq.), and N,N'-dicyclohexylcarbodiimide (DCC) (42 mg, 0.202 mmol, 0.44 eq.) were 
added into a 5 mL round bottom flask. DMF (1 mL) was added to dissolve the solid and 
the reaction was stirred at room temperature overnight. The reaction mixture was then 
filtered using a 0.2 μm Millex-GN nylon syringe filter (EMD Millipore; Billerica, MA) to 




ether. After centrifugation, the upper layer was decanted and the solid was re-dissolved 
with dichloromethane (DCM). The solution was then added dropwise into diethyl ether for 
a second precipitation and the solution was centrifuged again to collect the conjugate. The 
conjugate was isolated as a white powder (172 mg, 75% from PGC-g-SA). The percentage 
of PTX loading was determined via 1H NMR by integrating the peaks that correspond to 
the methine proton on the polymer backbone and the C2’ proton on the PTX side chain 
(Figure 2.18). 
2.4.5 Synthesis of PGC-PTX-Rho 
 PGC (100 mg, 0.85 mmol, 1.0 eq), rhodamine B isothiocyanate (36.4 mg, 0.068 
mmol, 0.08 eq), and DMF (1 mL) were added into a 5 mL round bottom flask. The reaction 
mixture was stirred at room temperature for 6 hours. Succinic anhydride (93 mg, 0.93 
mmol, 1.1 eq.) and DMAP (5.2 mg, 0.042 mmol, 0.05 eq.) were then added, and the 
reaction was stirred at room temperature overnight. The reaction mixture was then added 
dropwise into diethyl ether. After centrifugation, the upper layer was decanted and the solid 
was re-dissolved with an ethyl acetate/methanol mixture (3:2). The solution was then added 
dropwise into diethyl ether for a second precipitation, and the mixture was centrifuged 
again to collect the polymer. The isolated polymer was allowed to dry on vacuum 
overnight, and the polymer was isolated as red foam. Subsequently, PTX (157 mg, 0.183 
mmol, 0.4 eq.), DCC (42 mg, 0.202 mmol, 0.44 eq.), and DMF (1 mL) were added to the 
polymer, and the solution was stirred at room temperature overnight. The reaction mixture 
was then filtered using a 0.2 μm Millex-GN nylon syringe filter (EMD Millipore; Billerica, 




After centrifugation, the upper layer was decanted and the solid was re-dissolved with 
DCM. The solution was then added dropwise into diethyl ether for a second precipitation 
and the solution was centrifuged again to collect the PGC-PTX-Rho conjugate. PGC-PTX-
Rho was isolated as a dark red powder (201 mg, 55% from PGC). The percentage of PTX 
drug loading and rhodamine conjugation were determined via 1H NMR (Figure 2.19). 
2.4.6 Nanoparticle Formulation 
 NPs were prepared using a miniemulsion synthesis procedure. Briefly, 10-50 mg 
of polymer were dissolved in 0.5 mL DCM and added to a 2 mL solution of sodium dodecyl 
sulfate (SDS) in pH 7.4 10 mM phosphate buffer at a 1:5 SDS:polymer mass ratio. The 
mixture was then emulsified under an argon blanket using a Sonics Vibra-Cell VCX-600 
Ultrasonic Processor (Sonics & Materials; Newtown, CT). Following sonication, the NP 
suspension was subjected to stirring under argon for 2 hours, followed by stirring under air 
overnight to allow for the evaporation of remaining solvent. The resulting NP suspension 
was dialyzed for 24 hours against 1 L of 5 mM pH 7.4 phosphate buffer. The dialysis buffer 
was exchanged with fresh buffer after 10 hours of dialysis. PGC-PTX-Rho NPs used for in 
vivo peritoneal distribution studies were formulated using 1% (w/w) PGC-PTX-Rho 
polymer (10 mol% Rho, 41 mol% PTX) in combination with 40 mol% PTX PGC-PTX 
polymer (40% PGC-PTX). PGC-PTX-Rho NPs used in in vitro studies were formulated 




2.4.7 Calculation and Confirmation of Nanoparticle Paclitaxel Loading 
 NPs were prepared using conjugates of known PTX loading, as determined via 1H 
NMR by integrating the peaks that correspond to the methine proton on the polymer 
backbone and the C2’ proton on the conjugated PTX (Figure 2.18). PTX incorporation in 
molar ratio was then converted to mass ratio, and this value was used to calculate NP PTX 
concentration from a known PGC-PTX NP concentration. To confirm the incorporation of 
all added polymer into the resultant NP solution, NPs were diluted in acetonitrile to achieve 
a concentration of 20 μg/mL PTX. The absorbance of the solution at 227 nm was then 
determined using a Hewlett Packard 8453 UV-Vis Spectrophotometer (The Hewlett-
Packard Company; Palo Alto, CA). A set of PGC-PTX polymer standards was used to 
correlate absorbance to PTX concentration. A linear standard curve was developed 
(R2=0.999) and used to confirm PTX loading. PTX loading is reported as ± 1 mol%. 
2.4.8 Nanoparticle Diameter, Polydispersity, and Zeta Potential 
 Dynamic light scattering (DLS) was used to measure particle diameter, PDI, and 
zeta potential using a Brookhaven 90Plus Particle Size Analyzer (Brookhaven Instruments 
Corporation; Holtsville, NY). NPs were diluted in DI water in order to achieve a count rate 
of approximately 150 kilocounts per second. Zeta potentials were measured using the 
Brookhaven Instruments Corporation ZetaPALS zeta potential analyzer via the 
Smoluchowski method. Data presented are the averages of number-weighted size 
distributions ± standard deviation of three independently prepared samples per NP 





2.4.9 Nanoparticle Visualization via Scanning Electron Microscopy 
A Zeiss SUPRA 55VP field emission scanning electron microscope (FE-SEM) 
(Carl Zeiss Microscopy; Jena, Thuringia, Germany) was used to visualize NPs. Samples 
were prepared by diluting the NP suspension 1000x in DI water, and dropping a 10 μL 
aliquot on a silicon wafer. After samples were allowed to air-dry overnight, they were 
coated with Au/Pd using a Cressington 108 Manual Sputter Coater (Cressington Scientific 
Instruments; Watford, England, UK). 
2.4.10 Storage Stability 
 The 39% PGC-PTX NPs were synthesized and the starting diameters were 
measured using DLS. The initial free/unconjugated PTX content was determined by 
reversed-phase high performance liquid chromatography (HPLC) using a 7:3 
acetonitrile:water solution as the eluent at a flow rate of 0.5 mL/min through a HxSil C18 
4.6 x 250 mm column (Hamilton Robotics; Reno, NV) with a ProStar 335 Diode Array 
Detector (Varian, Inc; Palo Alto, CA). A set of free PTX standards was used to correlate 
the integrated area under the peak, at an absorbance of 228 nm, to concentration. Three 
linear standard curves were developed (0.1-5 μg/mL [R2=0.989], 5-50 μg/mL [R2=0.997], 
and 50-500 μg/mL [R2=0.999]) and used to determine unknown PTX concentrations. To 
prepare the NP solutions for HPLC analysis, 30 μL of NP suspension was added to 970 μL 
acetonitrile, vortexed for 1-2 minutes, and filtered using a 0.2 μm Millex-GN nylon syringe 
filter (EMD Millipore; Billerica, MA). 
Following initial NP characterization, half of the NP solution was stored at 4°C, 




20°C. After 1, 2, 3, 4, 5, 10, 15, 20, 30, 45, 60, 90, 120, or 180 days of storage, lyophilized 
NPs were resuspended in 70 μL of pH 7.4 10 mM phosphate buffer. At the given time-
points, both resuspended NPs as well as NPs stored at 4°C were characterized in order to 
determine NP diameter and free PTX content. After 90 and 180 days of storage, NPs were 
visualized via SEM. Data represents the average ± standard deviation of N=3/group. 
Statistical analysis was performed with two-way ANOVA. 
2.4.11 Paclitaxel Release Kinetics 
 Release medium was prepared by adding 0.3% w/w SDS to 10 mM pH 7.4 
phosphate buffer following a published procedure to ensure sink conditions299. 34% or 44% 
PGC-PTX NPs (1.98 mg PTX equivalent) were diluted with release medium to achieve a 
total volume of 10 mL. This solution was then placed into 10,000 molecular weight cutoff 
dialysis tubing, and the tubing was placed into 290 mL of release buffer stirring at 37°C. 
At given time-points, 400 μL samples were withdrawn from the release medium and 
replaced with fresh release buffer. The withdrawn samples were immediately quenched 
with 800 μL cold acetonitrile, vortexed for 20 seconds, and stored at -20°C. In a separate 
experiment, PTX degradation kinetics were evaluated by adding 1.98 mg PTX to 300 mL 
release buffer stirring at 37°C. At given time-points, 400 μL samples were withdrawn from 
the release medium, immediately quenched with 800 μL cold acetonitrile, vortexed for 20 
seconds, and stored at -20°C. PTX content was determined using a Q Exactive Plus hybrid 
quadrupole-orbitrap mass spectrometer (Thermo Scientific; Waltham, MA) with an 
electrospray ionization source coupled to an Acquity UPLC system (Waters Corp.; 




C18 2.1 x 50 mm column using a binary solvent gradient consisting of water with 0.1% 
formic acid and acetonitrile with 0.1% formic acid. The mass spectrometer was operated 
in positive ionization mode over a scan range of 500-2000 at a resolution of 35,000 with 
the following settings: spray voltage set at 3700 V, capillary temperature set at 256°C, 
sheath gas pressure set to 35, auxiliary gas pressure set to 15, sweep gas set to 2.25, heater 
temperature set to 412°C, and S-Lens RF level set to 75. An external standard curve, 
prepared using 2-fold dilutions of a PTX standard from 1 to 2000 nM in 1:3 release 
buffer:acetonitrile, was used to determine PTX concentration. Peak area of the extracted-
ion chromatogram for m/z 854.3387 ± 5 ppm was plotted against calculated concentrations 
and subjected to linear regression with a 1/x2 weighting. Data represents the average ± 
standard deviation of N=3/group. Statistical analysis was performed with two-way 
ANOVA.  
A conservative approach was utilized to compensate for PTX degradation (Figure 
2.20). We assumed that drug released between time-points t1 and t2, δM(t2), was released 
immediately before sample collection at t2 and was thus not affected by degradation. 
However, PTX content measured at t1, M(t1,measured), exhibits degradation over the time 
period (t2 - t1), or δ. Therefore at t2, M(t1,measured) has a new value Dδ*M(t1,measured), where 
Dδ is the known ratio of PTX remaining after δ time as determined from PTX degradation 
kinetics. Knowing M(t1,measured), M(t2,measured), and Dδ, we can calculate δM(t2) using the 
following relationship: M(t2,measured) = Dδ*M(t1,measured) + δM(t2). Therefore, the corrected 
cumulative amount of drug released by time-point t2, M(t2,corrected) = M(t1,corrected) + δM(t2). 




PTX release and degradation kinetics. The assumption used in this approach provides 
minimum values for release, and true values may be higher.  
2.4.12 Cell Culture 
 MSTO-211H, MSTO-211H-luc (firefly luciferase gene transfected MSTO-211H 
cells, MSTO-211H/CMMPnlacZ/LucNeo [5/11/04T]), and A549 cells (ATCC; Manassas, 
VA) were cultured in Roswell Park Memorial Institute (RPMI) medium supplemented with 
10% fetal bovine serum (FBS) and 1% penicillin−streptomycin. PANC-1 and MDA-MB-
231 cells (ATCC) were cultured in Dulbecco's Modified Eagle Medium (DMEM) 
supplemented with 10% FBS and 1% pencillin-streptomycin. Cells were maintained at 
37°C with 5% CO2 in a humidified environment.  
2.4.13 In Vitro Cytotoxicity 
 MSTO-211H, PANC-1, A549, and MDA-MB-231 cells were seeded in 96-well 
plates at densities of 3000, 4000, 1000, and 4000 cells/well, respectively, and allowed to 
adhere for 24 hours. On each plate, blank wells (media only) were defined as 0% viability, 
and wells with untreated cells were defined as 100% viability. Dilutions of PGC-PTX NPs 
(34, 39, and 43 mol% PTX; or 58, 61, and 64 wt% PTX, respectively), PTX formulated in 
Cremophor EL/ethanol (1:1 v/v; PTX-C/E), or PTX-SA-C/E were prepared, and cells were 
treated with 5000, 1000, 500, 100, 50, 10, 5, 1, 0.5, or 0.1 ng/mL PTX for 5 days. Cells 
were also treated with poly(benzyl 1,2-glycerol carbonate) (PGC prior to debenzylation; 
PGC-Bn) NPs as a drug-free NP control (administered at equivalent PGC backbone 




0.40, 0.20, 0.04 ng/mL PGC backbone equivalent) for 5 days. MSTO-211H cells were 
additionally treated with SDS alone (administered at equivalent concentrations to those 
employed in the 34% PGC-PTX NP formulation: 1813.66, 362.73, 181.37, 36.27, 18.14, 
3.63, 1.81, 0.36, 0.18, 0.04 ng/mL SDS) for 5 days. Viability was assessed using the 3-
(4,5-dimethylthiazol-2-yl)-5(3-carboxymethonyphenol)-2-(4-sulfophenyl)-2H-
tetrazolium (MTS) assay (CellTiter 96 Aqueous One, Promega; Madison, WI). The 
absorbance at 492 nm was determined using a Beckman Coulter AD 340 plate reader 
(Beckman Coulter Inc.; Brea, CA). The percent viability was determined by subtracting 
the average of media blanks and normalizing the absorbance of each well to the average 
absorbance of the untreated cells. The 50% inhibitory concentrations, or IC50 values, were 
determined by fitting the resultant data to sigmoidal four-parameter logistic curves using 
GraphPad Prism (GraphPad Software, Inc.; La Jolla, CA). Each curve represents the 
average of three experiments in which n=6-8/treatment group. To determine the maximum 
concentration of PGC-PTX-Rho NPs that can be administered within 24 hours without 
inducing cell death, MSTO-211H cells were seeded in 96-well plates (N=3) at a density of 
15,000 cells/well and allowed to adhere for 24 hours. Cells were treated with dilutions of 
40% PGC-PTX NPs and viability was assessed after 24 hours using the MTS assay as 
described previously (n=8/treatment group).  
2.4.14 In Vitro Cellular Uptake: Flow Cytometry 
 MSTO-211H cells were seeded in 6-well plates at a density of 300,000 cells/well 
and allowed to adhere for 24 hours. Cells were then incubated with PGC-PTX-Rho NPs at 




that can be administered as PGC-PTX NPs (40 mol% PTX) without inducing cell death 
after 24 hours of exposure (>95% cell viability; Figure 2.10). After 0, 0.5, 1, 2, 4, or 24 
hours of incubation (N=3/time-point), wells were rinsed 3x with 1 mL/well Dulbecco’s 
phosphate buffered saline (PBS) without calcium or magnesium. The cells were detached 
with 0.5 mL/well trypsin-EDTA (0.25%), and 2 mL media was added to each well to collect 
the cells. The cells were pelleted via centrifugation at 1000 RPM for 5 minutes, and the 
supernatant was removed. The cells were then resuspended in 3 mL 4% formaldehyde and 
incubated for 15 minutes. Cells were washed by adding 5 mL cold fluorescence-activated 
cell sorting (FACS) buffer (0.1% sodium azide, 1% BSA in PBS) and resuspending. The 
cell suspensions were centrifuged at 1000 RPM for 5 minutes, the supernatant was 
removed, and the cells were resuspended in 0.75 mL FACS buffer. Fluorescence was 
evaluated using a BD LSRII flow cytometer (BD Biosciences; Franklin Lakes, NJ), with 
10,000 events (single cells) recorded per sample. FACSDiva (Version 6.2; BD 
Biosciences) software was used to quantify cells which had internalized NPs (i.e., positive 
cells). These were defined as cells which exhibited higher fluorescence than 99% of the 
control/untreated population. 
2.4.15 In Vitro Cellular Uptake: Confocal Microscopy 
 MSTO-211H cells were seeded in 6-well plates at a density of 200,000 cells/well 
and allowed to adhere for 24 hours onto 25 mm diameter, # 1.5 thickness, sterile, Poly-L-
lysine coated coverslips (Neuvitro Corporation; Vancouver, WA). Cells were then 
incubated with PGC-PTX-Rho NPs at a dose of 100 ng/mL PTX, as previously described. 




formaldehyde for 20 minutes. The coverslips were rinsed 2x with 1 mL/well PBS, and 
incubated for 8 minutes with 100 μg/mL Concanavalin A-fluorescein conjugate 
(ThermoFisher Scientific; Waltham, MA) for membrane staining and 3 μg/mL Hoechst 
33342 trihydrochloride trihydrate (ThermoFisher Scientific) for nuclear staining. Wells 
were washed 2x with 1 mL/well PBS, and coverslips were mounted onto glass slides using 
ProLong Gold Antifade Mountant (ThermoFisher Scientific). Slides were visualized using 
a Zeiss LSM 710 confocal microscope (Carl Zeiss Microscopy; Jena, Thuringia, Germany). 
Images were analyzed using ImageJ software (NIH; Bethesda, MD). 
2.4.16 Animals Used in In Vivo Studies 
 Athymic female mice (6-8 week old NU/J; The Jackson Laboratory; Bar Harbor, 
ME) were housed at the animal facility of Dana Farber Cancer Institute (Boston, MA) 
under sterile conditions. Animal care and procedures were conducted with Institutional 
Animal Care and Use Committee approval, in strict compliance with all federal and 
institutional guidelines for the care and use of laboratory animals. 
2.4.17 In Vivo Nanoparticle Safety 
 Three healthy NU/J mice received a 140 mg/kg PTX dose as 34% PGC-PTX NPs 
via intraperitoneal (IP) injection. Mice were housed with free access to food and water, and 
were euthanized 120 days after IP injection. Two healthy NU/J mice of the same age served 
as untreated controls, and were housed for more than two weeks in separate cages at the 
same animal facility. Tissues including heart, lung, liver, spleen, kidney, and intestine were 




eosin (H&E). Pathological evaluation was performed by a licensed pathologist (R.F.P.).  
2.4.18 In Vivo Nanoparticle Peritoneal Distribution 
 Three weeks after IP tumor inoculation (5x106 MSTO-211H-luc cells), animals 
received an IP 100 uL/10 g injection of either PGC-PTX-Rho NPs (n=3) or rhodamine 
(n=2) in saline at a concentration of 0.03 mg/mL rhodamine. Three days after injection, 
animals were sacrificed and digital photographs using automatic exposure were taken using 
a customized, computer-controlled Canon digital camera under ambient light as well as 
ultraviolet (302 nm) light emitted from a Wood’s lamp (UVLMS-38 EL 3UV Lamp, UVP 
LLC; Upland, CA). 
2.4.19 In Vivo Prevention of Tumor Establishment 
 Immediately following IP tumor inoculation (5x106 MSTO-211H-luc cells) and via 
separate injections, mice received IP treatments of either 140 mg/kg PTX as 34% PGC-
PTX NPs (56 mg/kg PGC backbone), PGC-Bn NPs (58 mg/kg PGC backbone), 20 mg/kg 
PTX-C/E, 20 mg/kg PTX-C/E per day for 7 days, or 20 mg/kg PTX-C/E per week for 7 
weeks (n=8/group). Tumor burden was evaluated via bioluminescence imaging (BLI) at 4 
and 6 weeks after tumor inoculation (3 of the 8 mice per group being randomly selected at 
the beginning of the study). Images of mice were taken 10 minutes after subcutaneous 
injections of 2.25 mg firefly luciferin, using a Xenogen IVIS-50 bioluminescence camera 
(Caliper Life Sciences; Hopkinton, MA). The exposure setting was 60 s exposure, F4, small 
bin, and distance of 25 cm. All animals were monitored for tumor burden three times a 




than 15%, large palpable abdominal solid tumor, slow movement, and/or difficulty 
obtaining food and water. Overall survival was described by the Kaplan-Meier method and 
compared via log-rank test.  
2.4.20 In Vivo Treatment of Established Tumor 
 We also studied PGC-PTX NP efficacy in an established tumor model294. Briefly, 
one week after IP tumor inoculation (5x106 MSTO-211H-luc cells), animals received one 
of the following IP treatments: 140 mg/kg PTX as 34% PGC-PTX NPs (56 mg/kg PGC 
backbone), PGC-Bn NPs (58 mg/kg PGC backbone), saline, or 20 mg/kg PTX-C/E per 
week for 7 weeks (n=8/group). Tumor burden was evaluated via BLI at 4 and 6 weeks after 
tumor inoculation as previously described, and overall survival was described by the 
Kaplan-Meier method and compared via log-rank test.  
2.4.21 Statistics 
 All data are reported as mean ± standard deviation. Differences between groups 
were evaluated using one-way ANOVA, two-way ANOVA, or log-rank test using 
GraphPad Prism (GraphPad Software, Inc.; La Jolla, CA). Animals were randomly 
assigned to treatment groups. At the beginning of the in vivo efficacy studies, a subset of 
the animals (n=3) in each group was randomly chosen for subsequent BLI. No blinding 






Figure 2.1 Synthesis of PGC-PTX. PGC is synthesized by the copolymerization of benzyl 
glycidyl ether with carbon dioxide followed by debenzylation hydrogenation. PGC is then 










Figure 2.2 Characterization of PTX-SA. Proton NMR spectra of (a) PTX and (b) PTX-SA 
acquired in chloroform-d at 500 MHz. After conjugation of SA, the PTX CH proton on 
C2’ (indicated by an asterisk) shifts from 4.79 to 5.51 ppm, confirming the conjugation of 






Figure 2.3 70% PGC-PTX NP characterization. Scanning electron micrograph of PGC-
PTX NPs with 70 mol% (74 wt%) PTX loading shows a polydisperse particle population 
with NPs between 10-90 nm. Since 70% PGC-PTX NPs exhibit high dispersity and 







Figure 2.4 Formulation of PGC-PTX NPs. PGC-PTX NPs are prepared by emulsifying the 







Figure 2.5 Characterization of PGC-PTX NPs. (a) DLS size measurements of drug-free 
PGC-Bn NPs and PGC-PTX NPs with varying PTX loadings in mol%. (b) SEM 
micrograph of PGC-PTX NPs. (c) Polydispersity indices and (d) zeta potentials of PGC-
Bn and PGC-PTX NPs as measured by DLS. Data is presented as mean ± standard 








Figure 2.6 PGC-PTX NP storage stability. PGC-PTX NPs were stored in solution at 4°C 
or lyophilized, stored at -20°C, and resuspended at given time-points. (a) NP diameter and 
(b) free/unconjugated PTX content were evaluated over the course of 6 months of storage. 
SEM micrographs of NPs stored as (c,e) a solution or as (d,f) a lyophilized powder after 
(c,d) 90 and (e,f) 180 days of storage. Experiments were performed in triplicate, with data 
presented as mean ± standard deviation. Statistical analysis performed via two-way 
ANOVA confirmed that NP diameter and free PTX content do not differ between day 0 
and day 180 samples. Similarly, after 180 days of storage, NPs stored in solution do not 
exhibit differing size or free PTX content from NPs stored as a lyophilized powder. 






Figure 2.7 PGC-PTX NP release kinetics. PTX release kinetics from 34% and 43% PGC-
PTX NPs at 37°C in 0.3% SDS pH 7.4 phosphate buffer at (a) early time-points (<10 days) 
and over (b) 70 days. All experiments were performed in triplicate, with data presented as 







Figure 2.8 Activity of PGC-PTX NPs against cancer cells in vitro. (a) MSTO-211H, (b) 
A549, (c) PANC-1, and (d) MDA-MB-231 cells were treated with PGC-PTX NPs with 
varying PTX loadings in mol%, PTX-C/E, PTX-SA-C/E, or drug-free PGC-Bn NPs (given 
at equivalent PGC backbone concentrations to 34% PGC-PTX NPs). Cell viability was 
assessed after 5 days of treatment. All experiments were performed in triplicate, with data 







Figure 2.9 SDS cytotoxicity in MSTO-211H cells. Cells were treated with SDS at 
equivalent concentrations to those employed in the 34% PGC-PTX NP formulation, and 
viability was assessed after 5 days of exposure. Data are presented as the mean ± standard 







Figure 2.10 MSTO-211H cell viability 24 hours after treatment with 40% PGC-PTX NPs. 
At PTX doses ≤100 ng/mL, cell viability exceeds 95%. Data are presented as the mean ± 







Figure 2.11 Cellular internalization of PGC-PTX-Rho NPs. Uptake of PGC-PTX-Rho NPs 
was measured over time in MSTO-211H cells using flow cytometry. (a) A sample set of 
histograms shows increased fluorescence intensity of the cell population over time. (b) 
Positive cells are defined as cells which exhibit higher fluorescence than 99% of the 
control/untreated population. Data are presented as mean ± standard deviation of three 
individual experiments. (c) Laser-scanning confocal microscope image of MSTO-211H 
cells after 24 hours of incubation with PGC-PTX-Rho NPs. Image presented is the 2-D 
projection of a 3-D, 6 μm z-stack. Orthogonal views are shown on the periphery. Cell 
membranes are visualized in green, nuclei in blue, and NPs in red. NPs are diffuse in the 






Figure 2.12 Evaluation of 34% PGC-PTX NP safety. Healthy mice received 34% PGC-
PTX NPs at a dose of 140 mg/kg PTX via IP administration. Animals maintained healthy 
body weight during the 120-day survey period. Data are presented as mean ± standard 







Figure 2.13 Histological evaluation of major organs following PGC-PTX NP treatment. 
Healthy mice received 34% PGC-PTX NPs at a dose of 140 mg/kg PTX via IP 
administration. Liver (20x), kidney (20x), spleen (10x), intestine (20x), lung (10x), and 
heart (20x) tissue were harvested from treated animals and compared with untreated 
controls via histological evaluation by a licensed pathologist. The tissues harvested from 
the treated animals showed no pathologic changes, and were indistinguishable from the 






Figure 2.14 In vivo peritoneal distribution of PGC-PTX NPs. Three weeks after IP tumor 
inoculation, mice received either (a) rhodamine or (b) PGC-PTX-Rho NPs at equivalent 
rhodamine doses. Three days after injection, the peritoneum was assessed under (left) 
ambient and (right) ultraviolet light. The largest IP tumors are circled in yellow in each 
image. PGC-PTX-Rho NPs are visualized primarily in areas of tumor under ultraviolet 






Figure 2.15 In vivo efficacy of PGC-PTX NPs as a single dose in a prevention of peritoneal 
mesothelioma establishment model. Animals (n=8/group) received MSTO-211H-luc cells 
followed by same-day treatment. (a) Cumulative survival and (b) tumor burden of animals 
treated with PGC-Bn NPs, 20 mg/kg PTX-C/E, daily 20 mg/kg PTX-C/E for 7 days, 
weekly 20 mg/kg PTX-C/E for 7 weeks, or 140 mg/kg PTX via 34% PGC-PTX NPs. 
Bioluminescence data are presented as the mean ± standard deviation for three randomly 
assigned animals per group. Animals treated with a single dose of PGC-PTX NPs exhibit 
comparable survival to animals receiving weekly PTX treatment via log-rank test (p=0.77). 






Figure 2.16 In vivo efficacy of PGC-PTX NPs as a single dose in the treatment of 
established peritoneal mesothelioma. (a) Cumulative survival and (b) tumor burden of 
animals treated with saline, PGC-Bn NPs, weekly 20 mg/kg PTX-C/E for 7 weeks, or 140 
mg/kg PTX via 34% PGC-PTX NPs. Bioluminescence data are presented as the mean ± 
standard deviation for three randomly assigned animals per group. Animals treated with a 
single dose of PGC-PTX NPs exhibit comparable survival to animals receiving weekly 






Figure 2.17 Characterization of PGC-g-SA. (a) Proton and (b) carbon NMR spectra of 
PGC-g-SA. 1H and 13C spectra were acquired in DMSO-d6 at 500 and 125 MHz, 






Figure 2.18 Characterization of PGC-PTX. Sample (a) proton and (b) carbon NMR spectra 






Figure 2.19 Characterization of PGC-PTX-Rho. Proton NMR spectrum of PGC-PTX-Rho 






Figure 2.20 Degradation kinetics of free PTX. The degradation of PTX was evaluated at 
37°C in 10 mM pH 7.4 phosphate buffer supplemented with 0.3% SDS. Data is presented 




Table 2.1 Size exclusion chromatography characterization of PGC-Bn and PGC-PTX with 








Table 2.2 In vitro IC50 of PTX-C/E, PTX-SA-C/E, and PGC-PTX NPs with varying PTX 
loadings in mol% after 5 days of treatment. Concentrations noted in ng/mL PTX. Adapted 








CHAPTER 3: Reinforcement of Polymeric Nanoassemblies for Ultra-High Drug 




 The incorporation of chemotherapeutic agents into nanocarriers enhances the safety 
and efficacy of many anticancer agents, but the conundrum remains as to the optimal 
composition and role(s) of the carrier material138, 144, 187, 250, 251, 300, 301. Current research 
efforts primarily focus on the design of new materials and architectures with increased 
functionality and complexity. However, two outstanding design challenges hamper the 
optimization of nanocarrier mediated drug delivery: 1) maximization of drug/material 
efficiency (i.e., drug loading); and, 2) tunability of nanoparticle (NP) core properties. 
Achieving high drug/material efficiency in the development of drug carriers is imperative, 
as it has the potential to significantly reduce the costs of production, and additionally 
minimizes a patient’s exposure to synthetic carrier material. Control of NP core properties 
enables modulation of mechanical stiffness and release kinetics, affording an opportunity 
to further optimize nanocarrier drug delivery system performance and expand 
chemotherapy dosing protocols.  
 Polymer-drug conjugate nanocarriers with high drug loadings (i.e., drug:carrier 
mass ratios) of up to 74 wt% have been previously described151, 156, 269. However, these 
reports demonstrate a robust inverse correlation between conjugated drug content and in 




efficacy151, 163. Conversely, NPs with physically entrapped agents exhibit enhanced in vitro 
efficacy with increased drug loading302. Nanocarriers with physically entrapped agents 
nonetheless suffer from low drug loadings and significant burst release (>50% cumulative 
release in 24 hours)254. Therefore, the concurrent optimization of drug/material efficiency 
and system efficacy remains elusive. Furthermore, release kinetics and particle stiffness 
are implicated in nanocarrier efficacy162, 163, 185, 269, 303, 304. However, few studies focus on 
modulating the rate of drug liberation or mechanical stiffness in sustained release systems, 
especially within a single particle design and composition. Herein, we demonstrate the 
mechanical reinforcement of a novel poly(1,2-glycerol carbonate)-graft-succinic acid-
paclitaxel (PGC-PTX) conjugate nanocarrier via the addition of free paclitaxel (PTX) as a 
drug “binder” to achieve unprecedented ultra-high drug loadings of up to 105 wt%, and to 
modulate PTX release kinetics as well as nanocarrier stiffness. Importantly, increased PTX 
loading results in improved in vitro efficacy, without the need to compromise drug/material 
efficiency. In a murine model of peritoneal carcinomatosis, PGC-PTX NPs with additional 
physically entrapped PTX (i.e., PGC-PTX + PTX NPs) exhibit improved safety at high 
doses and significantly prolong survival even after a single intraperitoneal (IP) injection. 
 
3.2 Results and Discussion 
3.2.1 Synthesis of PGC-PTX 
Poly(1,2-glycerol carbonate) (PGC) is chosen as the novel scaffold for PTX 
conjugation as it readily degrades into biocompatible building blocks: glycerol and carbon 




primary hydroxy, enabling high and controlled PTX conjugation of up to 70 mol% or 74 
wt%151. PGC is synthesized by the ring-opening copolymerization of benzyl glycidyl ether 
with carbon dioxide, followed by deprotection via high pressure hydrogenolysis150, 274. 
PGC is then reacted with succinic anhydride and 4-dimethylaminopyridine (DMAP) to 
give PGC-graft-succinic acid (PGC-g-SA)151. PTX is subsequently incorporated via 
standard coupling chemistry using N,N’-dicyclohexylcarbodiimide (DCC) and DMAP to 
afford PGC-PTX with 34 mol% (58 wt%) PTX conjugation (Figure 3.1a). Since PGC-
PTX exhibits high PTX incorporation, we hypothesized that the compatibility (i.e., 
potential for physicochemical interactions) of free PTX with the PGC-PTX nanocarrier 
will enable the physical entrapment of large quantities of free drug, resulting in ultra-high 
PTX loadings. Additionally, due to the increased packing density, as well as non-covalent 
interactions between unconjugated and conjugated PTX, we theorized that the free drug 
will act as a binder, enabling modulation of both the mechanical properties and release 
kinetics of the nanocarrier. 
3.2.2 Formulation and Characterization of PGC-PTX + PTX Nanoparticles 
 PGC-PTX + PTX NPs are prepared by emulsification (Figure 3.1b). The core 
components, including PGC-PTX and free PTX, are dissolved in dichloromethane, while 
the surfactant, sodium dodecyl sulfate (SDS), is added to phosphate buffer. The mixture of 
the organic and aqueous solutions is then emulsified under an argon blanket via 
ultrasonication, and the resultant NP suspension is purified by dialysis. PGC-PTX + PTX 
NPs are formulated with up to 50 wt% additional physically entrapped drug, demonstrating 




is in stark contrast to the majority of drug carriers, which typically achieve <10 wt% drug 
loading by encapsulation due to less optimal compatibility between drug and carrier. In 
fact, encapsulation of celecoxib, a different hydrophobic active agent with a similar 
partition coefficient to PTX, does not exceed 10 wt% in PGC-PTX NPs. Similarly, 
poly(benzyl 1,2-glycerol carbonate) (PGC-Bn) NPs exhibit a maximum PTX encapsulation 
of 5 wt%, highlighting the importance of physicochemical interactions between free PTX 
and conjugated PTX. Previous work has likewise demonstrated that increasing the 
compatibility between a drug and its carrier, for example, via the incorporation of aromatic 
groups on the polymer chain, augments drug loading by physical entrapment (up to 35 wt% 
free drug)305-308. 
 PGC-PTX + PTX NPs exhibit sub-100 nm diameters, low dispersity, and negative 
zeta potentials due to the negative charge of the SDS surface coating (Figure 3.2 and 
Figure 3.3). NP size does not vary with free PTX loading, confirming the ability of the 
free drug binder to intersperse within the polymer network (Figure 3.2a). Likewise, the 
addition of free PTX does not impact the low dispersity of the PGC-PTX + PTX carriers, 
with all formulations exhibiting low polydispersity indices (PDIs) ≤0.1 (Figure 3.2b). PTX 
encapsulation efficiency (EE), or the portion of added free drug that is incorporated in the 
final NP suspension, exceeds 80% for all three formulations (Figure 3.4a). Interestingly, 
EE increases with escalating PTX loading, with the average loading efficiency reaching 
95% in the 50 wt% formulation. This trend indicates that increasing the density of PTX in 
the nanocarrier further promotes the incorporation of additional drug. Importantly, PGC-




wt%. Due to the high PTX incorporation in the polymer backbone as well as the enhanced 
ability to encapsulate large quantities of drug with high efficiency, PGC-PTX + PTX NP 
drug loading, or the ratio of PTX to carrier material, can be tuned from 58 wt%  (PGC-
PTX NPs) to 105 wt% (PGC-PTX + 50 wt% PTX NPs) (Figure 3.4b). Resultant PTX 
concentrations are therefore as high as 20 mg/mL, compared to PTX aqueous solubility of 
0.3 μg/mL281. 
3.2.3 Nanomechanical Properties 
 Due to the ability of PGC-PTX NPs to encapsulate free PTX at high density, we 
hypothesized that the free drug effectively reinforces the polymeric nanocarrier network 
via non-covalent interactions with conjugated PTX, rendering the free drug an effective 
binder for the modulation of mechanical properties on the nano-scale. To study nanocarrier 
mechanical properties, atomic force microscopy (AFM) was used to collect force curves, 
correlating cantilever tip indentation depth with force. Typical force curves display two 
regions with differing slopes (Figure 3.5a). The initial contact regime, resulting from 
indentation of the particle surface, reflects the mechanical properties of the particle itself. 
As the tip penetrates deeper into the material, the underlying stiff substrate influences the 
mechanical response, altering the slope of the force curve309. To obtain the elastic modulus 
of the nanocarriers, the Hertz’s model for non-adhesive elastic contact was used to correlate 
the loading force with indentation depth within the initial contact regime, spanning 5-50 
pN force and up to 50 nm indentation depth. Increased free PTX loading results in 
significant increases in nanocarrier elastic modulus (≥25 wt% PTX; Figure 3.5b). 




illustrating the importance of high loading capacity. PGC-PTX NPs and PGC-PTX + PTX 
NPs with 10, 25, and 50 wt% free PTX exhibit elastic moduli of 27.2 ± 9.5, 39.0 ± 9.9, 
55.2 ± 23.2, and 94.5 ± 20.1 kPa, respectively. These values are within the range of elastic 
moduli reported for swollen polymers such as highly cross-linked polyvinylpyrrolidone 
(40.8 ± 1.9 kPa)310, highly cross-linked polyacrylamide (34.8 ± 1.5 kPa)310, high density 
poly(N-isopropylacrylamide) (123 ± 9 kPa)311, and agar (40-90 kPa)312. The ability of PTX 
to mechanically reinforce the nanocarrier polymer network is attributed to increased 
packing density as well as interactions of the drug with the polymer scaffold. Similarly, 
crystal structures exhibit high stiffness due to high packing density and molecular order. 
To evaluate the stiffness of highly ordered PTX in the absence of a polymer network, PTX 
crystals were formed by emulsifying a solution of the free drug in an aqueous solution of 
SDS (Figure 3.6). PTX crystals exhibit an elastic modulus of 796 ± 565 MPa, four orders 
of magnitude greater than the polymeric nanocarrier formulations. Nonetheless, despite 
their high PTX loading, the PGC-PTX + PTX nanocarriers do not exhibit crystallinity as 
demonstrated by differential scanning calorimetry and x-ray powder diffraction analysis, 
confirming the random distribution of PTX within the entangled polymer network (Figure 
3.7 and Figure 3.8). This result is in agreement with previous reports demonstrating the 
amorphous configuration of active agents, including PTX and docetaxel, in polymeric 
carriers302, 313, 314. 
 Analysis of AFM retraction curves reveals long-range adhesive interactions 
between polymer chains in the nanocarrier matrix. All PGC-PTX + PTX NPs exhibit 




chromatography measurements illustrate that PGC-PTX exhibits an average molecular 
weight of 9,393 Da, corresponding to an 18-mer with an extended chain-length of 
approximately 16 nm151. This result suggests that many interacting chains are concurrently 
pulled by the AFM tip. Individual analysis of force retraction curve patterns for each 
formulation provides additional insight on molecular interactions within the polymeric 
core. While 93% of the retraction curves of PGC-PTX NPs reveal single peaks resembling 
the pulling of a polymer chain (Figure 3.5c), 7% show a saw-tooth pattern (Figure 3.5d), 
which is typically observed in the unfolding of a structured protein or the unzipping of a 
polymer fiber from a substrate315, 316. In the case of a polymeric nanocarrier, the saw-tooth 
pattern is likely due to the pulling and disruption of multiple, entangled polymer chains. 
The force extension curves of reinforced PGC-PTX + 10 wt% PTX NPs exhibit a greater 
incidence of saw-tooth patterns, at a frequency of 70%, demonstrating increased core 
interactions in the presence of free PTX. An additional 28% of retraction curves exhibit 
irregular plateau force curves (Figure 3.5e), while 2% reveal single peaks. Irregular plateau 
force curves result from stretching of the pulled chains, which is required to overcome 
increased interactions in the entangled polymer network317, 318. At 25 wt% free PTX 
loading, we observe 4% single peak stretching, 50% saw-tooth pattern, and 46% irregular 
plateau force curves. Finally, at the highest free PTX encapsulation of 50 wt%, we rarely 
observe extension curves, likely due to decreased adhesion between the tip and rigid 
polymer matrix. Among the few extension curves observed, 6% show single peaks, 29% 
show a saw-tooth pattern, and 65% show irregular plateau force curves. Taken together, 




properties as a function of physically entrapped PTX, which increases core stiffness and 
promotes polymer matrix stability via the augmentation of core interactions. 
3.2.4 Paclitaxel Release Kinetics and Characterization of Nanoparticles Following Drug 
Release 
 Subsequently, PTX release kinetics were evaluated by incubating the NPs in pH 
7.4 phosphate buffer for 15 days at 37°C (Figure 3.10). At given time-points, aliquots were 
collected from the release media and free PTX content was determined using liquid 
chromatography-mass spectrometry. PGC-PTX + PTX NPs exhibit tunable release 
kinetics, which are modulated by varying the free PTX content. Increasing the ratio of 
unconjugated:conjugated PTX via the physical entrapment of free drug affords facilitated 
release kinetics due to the ability of free PTX to diffuse from the polymeric matrix without 
the need for active cleavage from the polymer backbone. However, despite the high density 
of free PTX, an initial burst release is not observed, with all PGC-PTX + PTX NP 
formulations exhibiting sustained drug release due to the compatibility between PTX and 
the PGC-PTX carrier. PGC-PTX NPs and PGC-PTX + PTX NPs with 10, 25, and 50 wt% 
free PTX encapsulation exhibit 24%, 39%, 89%, and 77% cumulative PTX release within 
15 days, respectively (Figure 3.10b). While PGC-PTX + 50 wt% PTX NPs display 
accelerated drug release at early time-points (≤5 days) (Figure 3.10a), PGC-PTX + 25 
wt% PTX NPs demonstrate greater cumulative PTX release at later time-points (Figure 
3.10b). This result is likewise attributed to the increasing propensity of free PTX to interact 
with the nanocarrier matrix as overall PTX content is increased.  Interestingly, visualization 




indicates that both nanocarrier formulations exhibit a decrease in size following PTX 
release (Figure 3.11). However, nanomechanical characterization demonstrates that PGC-
PTX NPs maintain a stable elastic modulus throughout the 15-day release period, while 
PGC-PTX + 50 wt% PTX NPs exhibit significant reductions in stiffness with increased 
duration of release (Figure 3.12). These results are in agreement with the relatively rapid 
PTX release kinetics of the PGC-PTX + 50 wt% PTX NPs compared to the PGC-PTX NPs, 
and additionally demonstrate that liberation of PTX from the PGC-PTX + PTX nanocarrier 
core reduces core interactions and mechanical stiffness.  
3.2.5 In Vitro Efficacy 
 NP in vitro cytotoxicity was evaluated in MSTO-211H mesothelioma cancer cells 
after 5 days of exposure (Figure 3.13). Cells were treated with PGC-PTX NPs, one of the 
PGC-PTX + PTX NP formulations, the clinical formulation of PTX in a Cremophor 
EL/ethanol (1:1 v/v; C/E) excipient (PTX-C/E), or PGC-Bn NPs as a drug-free NP control. 
Cells treated with drug-free PGC-Bn NPs at equivalent PGC backbone concentrations to 
PGC-PTX NPs exhibit minimal cell death, with viabilities exceeding 80% at all 
concentrations. Due to the sustained release of active PTX from the PGC-PTX + PTX 
nanocarriers over an extended period of time, the in vitro potency after 5 days of exposure 
is reduced relative to PTX-C/E. Nonetheless, in contrast with previous reports, PGC-PTX 
+ PTX NP potency increases with greater PTX loading, with PGC-PTX + 50 wt% PTX 
NPs (105 wt% total PTX loading) exhibiting the greatest cytotoxic effect (Table 3.1). 
These results also correlate with PGC-PTX + PTX NP release kinetics at early time-points 




PGC-PTX + PTX NPs afford the concurrent optimization of nanocarrier drug loading and 
efficacy. 
3.2.6 Cellular Internalization 
 To evaluate the effect of rigidity on nanocarrier cellular internalization kinetics, 
MSTO-211H cells were incubated with either fluorescent, rhodamine-labeled PGC-PTX 
NPs or fluorescent, rhodamine-labeled PGC-PTX + 50 wt% PTX NPs. Nanocarrier 
internalization was subsequently monitored over the course of 4 hours via fluorescence 
activated cell sorting. Cells exhibiting greater fluorescence than 99% of the untreated, 
control population were considered positive for NP internalization. Our results demonstrate 
that the stiffer PGC-PTX + 50 wt% PTX NPs exhibit significantly increased cellular uptake 
at all time-points, with 96% of the cell population internalizing PGC-PTX + 50 wt% PTX 
NPs within 2 hours of treatment (Figure 3.14). Conversely, only 76% of cells internalize 
PGC-PTX NPs after 4 hours of exposure. This result is in agreement with previously 
published reports demonstrating greater cellular internalization of rigid nanocarriers 
relative to less rigid nanocarriers303, 304. Notably, conflicting reports regarding the effect of 
particle stiffness on cellular internalization warrant further and continued evaluation of 
tunable carriers319-321.  
3.2.7 In Vivo Safety 
 Due to the high aqueous concentrations of PTX as well as the continuous and 
sustained drug release afforded by the PGC-PTX + PTX nanocarriers, we hypothesized 




than PTX-C/E. A single dose of 140 mg/kg conjugated PTX can be safely administered in 
mice via PGC-PTX NPs151. To evaluate the safety of the analogous dual-loaded carriers, 
healthy mice were given a single IP injection of PGC-PTX + 25 wt% PTX NPs at a dose 
of 200 mg/kg PTX (140 mg/kg conjugated PTX + 60 mg/kg free PTX), and body weight 
was monitored over the course of two weeks post-administration. This formulation was 
chosen for initial evaluation as it has the median free drug loading among the NPs studied. 
Animals treated with PGC-PTX + 25 wt% PTX NPs exhibit an initial 10% reduction in 
body weight within two days after treatment (Figure 3.15), rendering 60 mg/kg (25 wt%) 
free PTX the maximum dose that can be safely administered. Nonetheless, animal weight 
increases after day 2 and returns to starting weight by day 14. Additionally, histological 
evaluation of the major organs after 14 days of PGC-PTX + 25 wt% PTX NP exposure 
does not reveal any adverse reactions relative to untreated animal controls, confirming that 
the treatment is well-tolerated (Figure 3.16). Therefore, a large dose of 200 mg/kg PTX 
can be safely administered via PGC-PTX + 25 wt% PTX NPs. In contrast, the maximum 
tolerated dose (MTD) of standard PTX-C/E in mice is reported between 13-50 mg/kg, 
while the median lethal dose (LD50) is 128 mg/kg
290-293. 
3.2.8 In Vivo Anticancer Efficacy 
 While sustained release is desirable for maintaining high local concentrations of 
active drug and minimizing toxicities associated with high peak tissue concentrations, Luo 
et al. report that among three PTX nano-conjugate systems exhibiting sustained release, 
the system exhibiting the most rapid release is the most efficacious in vitro and in vivo185. 




release kinetics correlate with improved in vitro efficacy162, 269. Due to the continuous and 
extended PTX release afforded by PGC-PTX nanocarriers, we previously demonstrated the 
utility of PGC-PTX NPs as a single high-dose replacement for multi-dose PTX treatment 
regimens in peritoneal mesothelioma151. A single IP injection of 140 mg/kg PTX via PGC-
PTX NPs affords comparable survival to PTX administered as seven doses of weekly 20 
mg/kg PTX-C/E151. However, we hypothesized that PGC-PTX + 25 wt% PTX NPs, which 
exhibit sustained PTX release over a period of 15 days compared to 70 days for PGC-PTX 
NPs, would significantly improve survival compared to the equivalent dose of PTX-C/E 
administered as a multi-dose treatment regimen. One week after IP tumor inoculation with 
luciferase-expressing MSTO-211H (MSTO-211H-luc) cells, mice were treated with either 
saline, a single dose of 200 mg/kg PTX via PGC-PTX + 25 wt% PTX NPs (140 mg/kg 
conjugated + 60 mg/kg unconjugated PTX), or weekly 20 mg/kg PTX-C/E for up to 10 
weeks (total PTX dose equivalent). Due to the toxicity of PTX-C/E, an equivalent single 
high-dose control cannot be administered. Additionally, daily 20 mg/kg PTX-C/E 
administrations result in a 63% acute mortality rate151. Therefore, a total PTX-C/E dose 
control must be administered as a weekly multi-dose treatment regimen. The study was 
concluded 8 weeks after tumor inoculation when >90% of control animals succumbed to 
disease. Animals treated with a single dose of PGC-PTX + 25 wt% PTX NPs exhibit 
significantly improved survival compared to multi-dose PTX-C/E treated animals 
(p=0.0105; Figure 3.17). Therefore, a single high dose of PGC-PTX + 25 wt% PTX NPs 
extends survival compared to multi-dose PTX-C/E, while polymer only PGC-PTX NPs 




of PGC-PTX + 25 wt% PTX NPs in the treatment of peritoneal carcinomatosis, in which 
the implementation of long-term regional chemotherapy is challenging despite 
demonstrating improved outcomes245, 246. 
 
3.3 Conclusions 
 In summary, PGC-PTX + PTX nanoassemblies are a distinctive drug delivery 
system which enables unprecedented ultra-high drug loadings >100 wt% via encapsulation 
of free drug in a high-density, drug-conjugated polymer. NP formulation is robust and 
reproducible, producing uniform sub-100 nm particles. The self-association and physical 
entrapment of free PTX binder affords the modulation of PTX loading, nanocarrier 
stiffness, and drug release kinetics. Despite the high density of free PTX (up to 50 wt%), 
all PGC-PTX + PTX NP formulations exhibit sustained and controlled PTX release over 
15 days, without any burst release effects. The continuous and sustained release of PTX 
from PGC-PTX + PTX nanocarriers affords improved in vivo safety at high PTX doses 
exceeding the LD50 of standard PTX-C/E. Importantly, PGC-PTX + PTX NPs enable the 
concurrent optimization of drug/material efficiency and system efficacy. PGC-PTX + PTX 
NPs with increased drug loadings exhibit improved in vitro efficacy. Similarly, a single 
high-dose of PGC-PTX + 25 wt% PTX NPs affords significantly improved survival in a 
murine model of peritoneal carcinomatosis compared to a multi-dose PTX-C/E treatment 
regimen, while polymer only PGC-PTX NPs exhibit equivalent efficacy to multi-dose 
PTX-C/E. Notably, these dual-loaded polymer-drug conjugate nanoassemblies present a 




concomitant realization of nanocarriers with previously unattainable ultra-high drug 
loadings, sustained release, and in vivo safety at high PTX doses opens new paradigms in 
the rational design of novel drug delivery systems and dosing protocols with transformative 
clinical potential. 
 
3.4 Materials and Methods 
3.4.1 Nanoparticle Preparation 
 Poly(1,2-glycerol carbonate)-graft-succinic acid-paclitaxel with 34 mol% (58 wt%) 
paclitaxel (PTX) conjugation (i.e., PGC-PTX) as well as PGC-PTX with 10 mol% 
rhodamine B conjugation were synthesized as previously described, and NPs were 
subsequently prepared by miniemulsion150, 151. Briefly, PTX was added to 10 – 50 mg PGC-
PTX polymer at 0, 10, 25, or 50 wt%. PGC-PTX and PTX were then dissolved in 0.5 mL 
dichloromethane, and added to a 2 mL solution of sodium dodecyl sulfate (SDS) in pH 7.4 
10 mM phosphate buffer at a 1:5 SDS:polymer mass ratio. The mixture was emulsified 
under an argon blanket using a Sonics Vibra-Cell VCX-600 Ultrasonic Processor (Sonics 
& Materials; Newtown, CT). Following sonication, the NP suspension was subjected to 
stirring under argon for 2 hours, followed by stirring under air overnight to allow for the 
evaporation of remaining solvent. The resulting NP suspension was dialyzed for 24 hours 
against 1 L of 5 mM pH 7.4 phosphate buffer. The dialysis buffer was exchanged with 
fresh buffer after 10 hours of dialysis. Drug-free poly(benzyl 1,2-glycerol carbonate) (PGC 
prior to debenzylation; PGC-Bn) NPs, PTX loaded PGC-Bn NPs, and celecoxib loaded 




same procedure was followed to emulsify free PTX into an SDS solution at a 1:5 SDS:PTX 
mass ratio. 
3.4.2 Characterization of Nanoparticle Diameter, Polydispersity, and Zeta Potential 
 Dynamic light scattering (DLS) was used to assess NP diameter, PDI, and zeta 
potential using a Brookhaven 90Plus Particle Size Analyzer (Brookhaven Instruments 
Corporation; Holtsville, NY). NPs were diluted in DI water in order to achieve a count rate 
of approximately 150 kilocounts per second. Zeta potentials were measured using the 
Brookhaven Instruments Corporation ZetaPALS zeta potential analyzer via the 
Smoluchowski method. Data presented are the averages of number-weighted size 
distributions ± standard deviation of three independently prepared samples per NP 
formulation. Statistical analysis was performed with one-way analysis of variance 
(ANOVA). 
3.4.3 Nanoparticle Visualization via Scanning Electron Microscopy 
 A Zeiss SUPRA 55VP field emission scanning electron microscope (FE-SEM) 
(Carl Zeiss Microscopy; Jena, Thuringia, Germany) was used to visualize NPs. Samples 
were prepared by diluting the NP suspension 1000x in DI water, and dropping a 10 μL 
aliquot on a silicon wafer. After samples were allowed to air-dry overnight, they were 
coated with Au/Pd using a Cressington 108 Manual Sputter Coater (Cressington Scientific 




3.4.4 Quantitation of Free Paclitaxel Encapsulation 
 Free PTX encapsulation was determined using reversed-phase high performance 
liquid chromatography (HPLC) using a 7:3 acetonitrile:water solution as the eluent at a 
flow rate of 0.5 mL/min through a HxSil C18 4.6 x 250 mm column (Hamilton Robotics; 
Reno, NV) with a ProStar 335 Diode Array Detector (Varian, Inc; Palo Alto, CA). A set 
of free PTX standards was used to correlate the integrated area under the peak, at an 
absorbance of 228 nm, to concentration. Three linear standard curves were developed (0.1-
5 μg/mL [R2=0.989], 5-50 μg/mL [R2=0.997], and 50-500 μg/mL [R2=0.999]) and used to 
determine unknown PTX concentrations. To prepare the NP solutions for HPLC analysis, 
30 μL of NP suspension was added to 970 μL acetonitrile, vortexed for 1-2 minutes, and 
filtered using a 0.2 μm Millex-GN nylon syringe filter (EMD Millipore; Billerica, MA). 
3.4.5 Calculation and Confirmation of Total Paclitaxel Loading 
 NPs were prepared using a conjugate with known PTX loading (34 mol%), as 
determined via 1H NMR by integrating the peaks that correspond to the methine proton on 
the polymer backbone and the C2’ proton on the conjugated PTX151. PTX incorporation in 
molar ratio was then converted to mass ratio (58 wt%), and this value was used to calculate 
NP PTX concentration from a known PGC-PTX concentration. Total PTX loading was 
determined by adding the conjugated PTX content and the physically entrapped PTX 
content (determined via HPLC). To confirm total PTX loading, NPs were diluted in 
acetonitrile to achieve a concentration of 20 μg/mL PTX. The absorbance of the solution 
at 227 nm was then determined using a Hewlett Packard 8453 UV-Vis Spectrophotometer 




was used to correlate absorbance to PTX concentration. A linear standard curve was 
developed (R2=0.999) and used to confirm PTX content. 
3.4.6 Nanomechanical Characterization 
 Atomic force microscopy (AFM) was performed using a MFP-3D microscope 
(Asylum Research; Santa Barbara, CA). The contact mode was applied using a silicon 
nitride tip (MLCT, Bruker AFM Probes; Camarillo, CA) with a nominal spring constant of 
40 pN/nm. Samples were prepared by diluting the suspensions 1000x in DI water, and 
dropping a 10 μL aliquot on a positively charged glass slide. NPs were immobilized by air 
drying overnight. Prior to imaging, samples were rehydrated by adding a 20 μL drop of DI 
water. An area scan was performed in tapping mode prior to indentation to confirm the 
presence and density of NPs (Figure 3.18). Force spectroscopy was then obtained over a 
250 nm extension length and a 500 nm/s approaching and retreating velocity. Force curves 
(N=100) were collected over an area of 500 x 500 nm2. The set-point was at 400 pN. We 
distinguished force curves resulting from a tip-particle interaction from those resulting 
from a tip-substrate interaction by (1) the height difference and, (2) the presence of the 
extension peak(s) upon retraction. To determine indentation depth, the cantilever’s inverse 
optical lever sensitivity (InvOLS; unit: m/V) was obtained by indenting the cantilever on a 
clean glass substrate. The glass substrate serves as an infinitely hard surface for 
determining the lever deflection response. Once an indentation was performed, the raw 
distance of the tip along the z-direction was converted into an indentation depth using the 
InvOLS. The cantilever stiffness was determined using the thermal tuning method, and 




different particles from different locations to take NP variability into consideration. Only 
single, non-aggregated particles were probed in these experiments. To determine the elastic 
modulus, we assumed the contact of two elastic materials. The Hertz’s model for non-
adhesive elastic contact was first used to determine the reduced elastic modulus as a result 
of the combined elasticities of the tip and sample by correlating the loading force, 𝐹, with 







Here, 𝜈 is the Poisson ratio of the sample (set to 0.33 for a polymer), and 𝛼 is the half 
opening angle of the indenting tip (36°). Finally, the sample modulus was calculated using 














The tip’s Young’s modulus was set to 290 GPa, with a Poisson ratio of 0.29 and a cone 
shape. Data was fitted for indentation depths of up to 50 nm, corresponding to 
approximately 50% of the total indentation needed to hit the infinitely hard glass substrate. 
This value was chosen empirically, based on both optimization of the goodness of fit 
(evaluated via the reduced chi-squared statistic) as well as the stability of the fitted 
parameter (elastic modulus). A representative set of data (from the PGC-PTX NP 
formulation; Figure 3.19) shows that the elastic modulus is stable within the range of 40-
60% indentation depth, and increases after 60% indentation depth due to the effect of the 
underlying stiff substrate. Meanwhile, the reduced chi-squared value is closest to 1 within 




(WaveMetrics Inc.; Portland, OR). Statistical analysis was performed with one-way 
ANOVA using GraphPad Prism. 
3.4.7 Differential Scanning Calorimetry 
 Calorimetry measurements were performed on PTX, PGC-PTX, PGC-PTX NPs, 
and PGC-PTX + 50 wt% PTX NPs using a Q100 differential scanning calorimeter (DSC) 
(TA Instruments; New Castle, DE). NP solutions were lyophilized in order to obtain dry 
samples. Samples were heated at rate of 10°C/min to 150°C, cooled at a rate of 5°C/min to 
-80°C, and heated at a rate of 10°C/min to 300°C. An empty aluminum pan was used as a 
reference in each measurement. 
3.4.8 X-ray Powder Diffraction 
 X-ray powder diffraction (XRPD) measurements were performed on PTX, PGC-
PTX, lyophilized PGC-PTX NPs, and lyophilized PGC-PTX + 50 wt% PTX NPs using a 
Bruker D8 Discover X-ray diffractometer (Bruker Corporation; Billerica, MA). 
Measurements were carried out using Cu-Kα radiation at 40 kV and 40 mA, with samples 
continuously scanned between 5° and 90° (2θ), at a step size of 0.02° and a rate of 1s/step. 
3.4.9 Paclitaxel Release Kinetics 
 PTX release kinetics were evaluated as previously described151. Briefly, release 
medium was prepared by adding 0.3% w/w SDS to 10 mM pH 7.4 phosphate buffer 
following a published procedure to ensure sink conditions299. PGC-PTX + PTX NPs (1.98 
mg PTX equivalent) were diluted with release medium to achieve a total volume of 10 mL. 




the tubing was placed into 290 mL of release buffer stirring at 37°C. At given time-points, 
400 μL samples were withdrawn from the release medium and replaced with fresh release 
buffer. The withdrawn samples were immediately quenched with 800 μL cold acetonitrile, 
vortexed for 20 seconds, and stored at -20°C. PTX content was determined using a TSQ 
Triple Quadrupole mass spectrometer (Thermo Scientific; Waltham, MA) with an 
electrospray ionization source coupled to an Acquity UPLC system (Waters Corp.; 
Milford, MA). A 7.5 µL injection of each sample was eluted from an Acquity UPLC HSS 
PFP 2.1 x 50 mm column using a binary solvent gradient consisting of water with 10 mM 
ammonium acetate and acetonitrile. The mass spectrometer was operated in positive 
ionization mode monitoring ion 876.3 with a scan width of 0.4 Da and a scan time of 0.05 
s.  The mass spectrometer utilized the following settings: heated electrospray ionization 
source spray voltage set at 3500 V with a vaporizer temperature of 376°C, capillary 
temperature set at 352°C, sheath gas pressure set to 60, auxiliary gas pressure set to 50, and 
sweep gas set to 2.  An external standard curve, prepared using two-fold dilutions of a PTX 
standard from 1 to 4096 nM in 1:3 release buffer:acetonitrile, was used to determine PTX 
concentration. Peak area of the extracted-ion chromatogram for m/z 877.3 was plotted 
against calculated concentrations and subjected to linear regression. A conservative 
approach was utilized to compensate for PTX degradation, as previously described151. Data 
represents the average ± standard deviation of N=3/group. Statistical analysis was 




3.4.10 Characterization of Nanoparticles Following Drug Release 
 PGC-PTX NPs and PGC-PTX + 50 wt% PTX NPs (1.98 mg PTX equivalent) were 
each diluted in release medium to achieve a total volume of 10 mL. The NP suspensions 
were then transferred into 10,000 molecular weight cutoff dialysis tubing and placed in 290 
mL of release buffer stirring at 37°C. After 7 and 15 days of release, NP samples were 
withdrawn from the dialysis tubing and prepared for visualization and nanomechanical 
characterization via SEM and AFM, respectively. 
3.4.11 Cell Culture 
 MSTO-211H and MSTO-211H-luc (firefly luciferase gene transfected MSTO-
211H cells, MSTO-211H/CMMPnlacZ/LucNeo [5/11/04T]) cells were cultured in Roswell 
Park Memorial Institute (RPMI) medium supplemented with 10% fetal bovine serum 
(FBS) and 1% penicillin−streptomycin. Cells were maintained at 37°C with 5% CO2 in a 
humidified environment. 
3.4.12 In Vitro Cytotoxicity 
 MSTO-211H cells were seeded in 96-well plates at a density of 3000 cells/well, 
and allowed to adhere for 24 hours. On each plate, blank wells (media only) were defined 
as 0% viability, and wells with untreated cells were defined as 100% viability. Dilutions 
of PGC-PTX NPs, PGC-PTX + PTX NPs, or PTX formulated in Cremophor EL/ethanol 
(1:1 v/v; PTX-C/E) were prepared, and cells were treated with 5000, 1000, 500, 100, 50, 
10, 5, 1, 0.5, or 0.1 ng/mL PTX for 5 days. Cells were also treated with PGC-Bn NPs as a 




PTX NPs; 2015.22, 403.04, 201.52, 40.30, 20.15, 4.03, 2.02, 0.40, 0.20, 0.04 ng/mL PGC 
backbone equivalent) for 5 days. Viability was assessed using the 3-(4,5-dimethylthiazol-
2-yl)-5(3-carboxymethonyphenol)-2-(4-sulfophenyl)-2H-tetrazolium (MTS) assay 
(CellTiter 96 Aqueous One, Promega; Madison, WI). The absorbance at 492 nm was 
determined using a Beckman Coulter AD 340 plate reader (Beckman Coulter Inc.; Brea, 
CA). The percent viability was determined by subtracting the average of media blanks and 
normalizing the absorbance of each well to the average absorbance of the untreated cells. 
The 50% inhibitory concentrations, or IC50 values, were determined by fitting the resultant 
data to sigmoidal four-parameter logistic curves using GraphPad Prism (GraphPad 
Software, Inc.; La Jolla, CA). Each curve represents the average ± standard deviation of 
three experiments in which n=6-8/treatment group. 
3.4.13 In Vitro Cellular Uptake 
 MSTO-211H cells were seeded in 6-well plates at a density of 300,000 cells/well, 
and allowed to adhere overnight. Cells were then incubated with rhodamine-labeled PGC-
PTX NPs or rhodamine-labeled PGC-PTX + 50 wt% PTX NPs at a concentration of 100 
ng/mL conjugated PTX. After 0, 1, 2, and 4 hours of incubation (N=3/group), wells were 
rinsed 3x with 1 mL/well Dulbecco’s phosphate buffered saline (PBS) without calcium or 
magnesium and cells were detached using 0.5 mL/well trypsin-EDTA (0.25%). The cells 
were then collected using 2 mL media/well, pelleted via centrifugation at 1000 RPM for 5 
minutes, and the supernatant was removed. Cells were subsequently fixed via resuspension 
in 3 mL 4% formaldehyde for 15 minutes. After fixation, cells were washed with 5 mL 




PBS), pelleted via centrifugation, and resuspended in 0.75 mL FACS buffer. The 
fluorescence of the cell population was evaluated using a BD LSRII flow cytometer (BD 
Biosciences; Franklin Lakes, NJ), with 10,000 events (single cells) recorded per sample. 
Data analysis was performed using the FACSDiva (Version 6.2; BD Biosciences) software. 
Cells exhibiting greater fluorescence than 99% of the untreated cell population were 
considered positive for NP internalization. Data represents the average ± standard 
deviation. Statistical analysis was performed with two-way ANOVA. 
3.4.14 Animals Used in In Vivo Studies 
 Athymic female mice (6-8 weeks old NU/J; The Jackson Laboratory; Bar Harbor, 
ME) were housed at the animal facility of Dana Farber Cancer Institute (Boston, MA) 
under sterile conditions. Animal care and procedures were conducted with Institutional 
Animal Care and Use Committee approval, in strict compliance with all federal and 
institutional guidelines for the care and use of laboratory animals. 
3.4.15 In Vivo Safety 
 Three healthy NU/J mice received a 200 mg/kg PTX dose as PGC-PTX + 25 wt% 
PTX NPs via IP injection. Mice were housed with free access to food and water, and were 
euthanized 14 days after IP injection. Two healthy NU/J mice of the same age served as 
untreated controls, and were housed for more than two weeks in separate cages at the same 
animal facility151. Tissues including heart, lung, liver, spleen, kidney, and small intestine 




hematoxylin and eosin (H&E). Pathological evaluation was performed by a licensed 
pathologist (R.F.P.). 
3.4.16 In Vivo Treatment of Established Tumor 
 PGC-PTX + PTX NP efficacy was evaluated in a model of established peritoneal 
mesothelioma as described previously151. Briefly, one week after IP tumor inoculation 
(5x106 MSTO-211H-luc cells), animals received one of the following IP treatments: 200 
mg/kg PTX as PGC-PTX + 25 wt% PTX NPs, saline, or 20 mg/kg PTX-C/E per week for 
up to 10 weeks (permitting animal survival) (n=8/group). All animals were monitored for 
tumor burden three times a week and were euthanized upon evidence of morbid disease 
including weight loss more than 15%, large palpable abdominal solid tumor, slow 
movement, and/or difficulty obtaining food and water. Overall survival was described by 
the Kaplan-Meier method and compared via log-rank test. Bonferroni correction was used 
to account for multiple comparisons, providing a statistical significance level of α = 0.02. 
3.4.17 Statistics 
 All data are reported as mean ± standard deviation. Differences between groups 
were evaluated using one-way ANOVA, two-way ANOVA, or log-rank test using 
GraphPad Prism (GraphPad Software, Inc.; La Jolla, CA). Animals were randomly 






Figure 3.1 Structure and formulation of PGC-PTX + PTX NPs. (a) Structure of PGC-PTX 
conjugate. (b) PGC-PTX + PTX NPs are formulated by emulsifying the polymer and free 








Figure 3.2 Characterization of PGC-PTX + PTX NPs. DLS evaluation of nanocarrier (a) 
size, (b) polydispersity, and (c) zeta potential. Data is presented as mean ± standard 







Figure 3.3 Visualization of PGC-PTX + PTX NPs. Scanning electron micrographs of (a) 
PGC-PTX NPs, (b) PGC-PTX + 10 wt% PTX NPs, (c) PGC-PTX + 25 wt% PTX NPs, and 







Figure 3.4 Nanocarrier drug loading. (a) Encapsulation efficiency of free PTX. (b) Total 
PTX loading of each NP formulation. Data is presented as the mean ± standard deviation 







Figure 3.5 Nanomechanical characterization of PGC-PTX + PTX NPs. (a) Representative 
force-indentation curve of a PGC-PTX NP. The solid line shows the region used for fitting 
using the Hertz’s model. (b) Elastic modulus of NP formulations (***p < 0.001, ****p < 
0.0001; compared to PGC-PTX NPs). Data is presented as mean ± standard deviation. 
Example force retraction curves showing (c) single extension peak in PGC-PTX NPs, (d) 
saw-tooth pattern in PGC-PTX + 10 wt% PTX NPs, and (e) irregular force plateau in PGC-







Figure 3.6 Scanning electron micrographs of PTX crystals formed by emulsifying a 






Figure 3.7 Representative DSC thermograms of PTX, PGC-PTX, PGC-PTX NPs, and 






Figure 3.8 Representative XRPD patterns of PTX, PGC-PTX, PGC-PTX NPs, and PGC-













Figure 3.10 Drug release kinetics. PTX release kinetics of PGC-PTX NPs and PGC-PTX 
+ PTX NPs at 37°C in pH 7.4 phosphate buffer at (a) early time-points (≤5 days) and (b) 
over 15 days. The experiment was performed in triplicate, with data presented as the mean 








Figure 3.11 Visualization of PGC-PTX + PTX NPs following drug release. Scanning 
electron micrographs of (a-c) PGC-PTX NPs and (d-f) PGC-PTX + 50 wt% PTX NPs (a,d) 








Figure 3.12 Characterization of particle stiffness following drug release. The elastic 
moduli of PGC-PTX NPs and PGC-PTX + 50 wt% PTX NPs were characterized before 








Figure 3.13 PGC-PTX + PTX NP in vitro cytotoxicity. MSTO-211H cells were incubated 
with non-drug loaded PGC-Bn NPs, PTX-C/E, or one of four NP formulations. Cell 
viability was evaluated after 5 days of exposure. All experiments were performed in 







Figure 3.14 Cellular internalization of fluorescent, rhodamine-labeled NPs in MSTO-
211H cells. Cells exhibiting greater fluorescence than 99% of the untreated population 







Figure 3.15 Evaluation of PGC-PTX + 25 wt% PTX NP safety. Healthy mice received 
PGC-PTX + 25 wt% PTX NPs at a dose of 200 mg/kg PTX via IP administration and 







Figure 3.16 Histological evaluation of major organs following PGC-PTX + 25 wt% PTX 
NP treatment. Healthy mice received PGC-PTX + 25 wt% PTX NPs at a dose of 200 mg/kg 
PTX via IP administration. Liver, kidney, spleen, small intestine, lung, and heart tissue 
sections were harvested from treated animals and stained with H&E. Images at 200x 
original magnification (scale bar = 50 μm). No pathologic changes were observed by a 







Figure 3.17 In vivo efficacy of PGC-PTX + 25 wt% PTX NPs as a single dose in the 
treatment of peritoneal mesothelioma. One week after IP tumor inoculation, mice were 
treated with saline, a single 200 mg/kg PTX dose via PGC-PTX + 25 wt% PTX NPs (140 
mg/kg conjugated PTX + 60 mg/kg free PTX), or weekly 20 mg/kg PTX-C/E for up to 10 
weeks (total dose control). Overall survival was monitored for 8 weeks post-tumor 
inoculation and compared via log-rank test (n=8 per group; *p=0.0105). Overall survival 
of animals treated with a single dose of 140 mg/kg PTX via PGC-PTX NPs in a separate 







Figure 3.18 Representative AFM image of NPs. After NPs are identified, force curves are 







Figure 3.19 Normalized elastic modulus and goodness of fit for force spectroscopy data as 
a function of cumulative indentation depth used for fitting. Elastic moduli are normalized 
by the elastic modulus derived from fitting the force-indentation depth data for up to 50% 
indentation depth. The elastic modulus is stable within the range of 40-60% indentation 
depth, and increases after 60% indentation depth due to the effect of the underlying stiff 
substrate. Meanwhile, the reduced chi-squared value is closest to 1 within the range of 40-





Table 3.1 In vitro 50% inhibitory concentrations (IC50s) of PTX-C/E, PGC-PTX NPs, and 
PGC-PTX + PTX NPs after 5 days of treatment in MSTO-211H mesothelioma cancer cells. 
IC50 values are derived from fitting the cell viability data to sigmoidal four-parameter 






CHAPTER 4: Synthesis and Evaluation of Polyglycerol Carbonate/Polyester Blend 
Nanocarriers for Paclitaxel Delivery 
 
4.1 Introduction 
 Polymeric nanoparticles (NPs) are widely investigated as cancer nanomedicines 
due to their ability to safely and effectively deliver chemotherapeutic agents138, 187, 251, 300. 
Particle properties, including size, shape, and surface coating have emerged as key 
parameters affecting the biological response of these carriers322. Additionally, nanoscale 
material properties significantly impact cell response and therapeutic efficacy163. In 
particular, particle rigidity has been shown to affect cellular internalization and potency163, 
303, 304, 319-321, 323. However, relatively few strategies exist to modulate the nanomechanical 
properties of colloidal drug carriers. Notably, conflicting reports regarding the effect of 
particle stiffness on cellular internalization and efficacy warrant the continued design, 
evaluation, and optimization of polymeric nanocarriers with tunable properties. Previously, 
we harnessed the compatibility of an unconjugated drug with its respective polymer-drug 
conjugate nanocarrier to increase core interactions and particle stiffness (Chapter 3). In the 
present work, we explore the modulation of nanocarrier core composition to reduce particle 
rigidity. 
 Polymer blend formulations are extensively explored for pharmaceutical and 
biomedical applications to afford new materials which harness and combine the properties 
of multiple polymers. Presently, polymer blend solid dispersions, scaffolds, nanofibers, 




second polymer can reduce the bulk stiffness of the original polymeric material by 
disrupting intermolecular forces329. We herein explore the utility of this approach in 
modulating the nanomechanical properties and in vitro efficacy of poly(1,2-glycerol 
carbonate)-graft-succinic acid-paclitaxel (PGC-PTX) NPs. Specifically, polymeric 
nanocarrier blends of PGC-PTX and poly(D,L-lactide-co-glycolide) (PLGA) are 
formulated, characterized, and evaluated for cytotoxic activity.  
Poly(1,2-glycerol carbonate) (PGC) is a biodegradable and biocompatible polymer 
synthesized by the copolymerization of benzyl glycidyl ether and carbon dioxide150. The 
pendant hydroxy functionality of the PGC backbone enables the covalent incorporation of 
paclitaxel (PTX) via a succinic acid linker to afford PGC-PTX with high PTX loadings of 
up to 70 mol%, or 74 wt% (Figure 4.1a)151. The formulation of PGC-PTX into nanocarriers 
is robust and produces monodisperse, sub-100 nm particles with prolonged storage stability 
of up to 6 months151. Importantly, PGC-PTX NPs demonstrate continuous and extended 
PTX release for periods of up to 70 days, affording sustained therapeutic efficacy in 
preclinical animal models of peritoneal carcinomatosis. The dual conjugation and physical 
entrapment of PTX in these carriers harnesses the physicochemical interactions between 
free and conjugated PTX to achieve unprecedented ultra-high drug loadings (>100 wt%) 
as well as facile and fine-tuned control of nanomechanical properties and release kinetics 
(Chapter 3). Free PTX acts as a crosslinker, increasing core interactions as well as particle 
stiffness. Similarly, we theorized that the incorporation of PLGA, a widely used 




stiffness by disrupting compact aggregation of the hydrophobic polymer in the nanocarrier 
core.  
 
4.2 Results and Discussion 
4.2.1 Formulation and Characterization of PGC-PTX/PLGA Blend Nanoparticles 
 PGC-PTX/PLGA NPs are prepared using PGC-PTX with 43 mol% (64 wt%) PTX 
incorporation and PLGA with a 1:1 ratio of glycolic acid to lactic acid. To evaluate the 
effect of polymer molecular weight, 30,000-60,000 Da high molecular weight (HMW) and 
7,000-17,000 Da low molecular weight (LMW) PLGA are utilized and incorporated at 
ratios of 1:4 and 1:19 PGC-PTX:PLGA. Nanocarriers are formulated using a miniemulsion 
procedure in which the core components, including PGC-PTX and PLGA are dissolved in 
dichloromethane, and added to an aqueous solution of the surfactant, sodium dodecyl 
sulfate (SDS) (Figure 4.1b). The mixture is emulsified under an argon blanket, and the 
resulting suspension is purified by dialysis. Prior to emulsification, the PGC-PTX and 
PLGA polymers form a clear solution in dichloromethane, indicating miscibility of the two 
polymers. Conversely, despite their high solubility in dichloromethane, a mixture of PGC-
PTX and poly(benzyl 1,2-glycerol carbonate), the PGC polymer prior to deprotection, 
exhibits phase separation, indicating that the two polymers are immiscible and do not form 
a homogenous mixture for particle formulation.  
By dynamic light scattering, the PGC-PTX NPs and the four PGC-PTX/PLGA NP 
formulations are of similar size, with average diameters between 63 and 83 nm (Figure 




greater polydispersity indices (PDIs) >0.12 compared to <0.09 for PGC-PTX NPs (Figure 
4.2b). The increased variation in size observed in the polymer blend nanocarriers is likely 
due to the increased heterogeneity of the polymer constituents due to the incorporation of 
PLGA with differing molecular weights and at varied ratios. All particle formulations 
exhibit negative zeta potentials <-30 mV resulting from the negative charge of the SDS 
surface coating (Figure 4.2c). Scanning electron micrographs demonstrate that PGC-
PTX/PLGA NPs possess smaller diameters and greater dispersity relative to PGC-PTX 
NPs (Figure 4.3). Compared to HMW PLGA NPs, PGC-PTX/HMW PLGA NPs exhibit 
smaller diameters. Meanwhile, PGC-PTX/LMW PLGA NPs are larger than LMW PLGA 
NPs. Interestingly, both 1:19 PGC-PTX/PLGA NP formulations additionally exhibit a 
relatively collapsed morphology suggesting greater deformation of the structures after 
drying (Figure 4.3d,g)320. 
4.2.2 Nanomechanical Properties 
 To evaluate nanomechanical properties, atomic force microscopy (AFM) was used 
to correlate cantilever indentation depth with force as previously described (Chapter 3). 
The elastic modulus was determined using the Hertzian model of non-adhesive elastic 
contact. The fitting was performed within the initial contact regime corresponding to an 
indentation depth of up to 25 nm and a force of up to 25 pN. Beyond the initial contact 
regime, the underlying stiff substrate influences the measurement and alters the slope of 
the force curves. Although a trend is observed suggesting that the elastic modulus decreases 
with greater PLGA content as well as reduced molecular weight, the nanomechanical 




PGC-PTX NPs (Figure 4.4). PGC-PTX NPs and PGC-PTX/PLGA NPs exhibit elastic 
moduli between 12 and 20 kPa, similar to polymeric hydrogel nanoparticles and 
microparticles with low crosslinker content320, 321.  
4.2.3 In Vitro Anticancer Efficacy 
 The in vitro potency of the PGC-PTX and PGC-PTX/PLGA nanocarriers was 
evaluated in MDA-MB-231 breast cancer cells after 5 days of treatment (Figure 4.5). In 
previous chapters, we demonstrated the efficacy of PGC-PTX NPs in the treatment of 
peritoneal mesothelioma. Herein, breast cancer cells are chosen for evaluation in order to 
explore the utility of PGC-PTX NPs in the treatment of a non-peritoneal solid cancer. As 
a control, cells were additionally treated with the clinical formulation of PTX in a 
Cremophor EL/ethanol (1:1 v/v; C/E) excipient (PTX-C/E). Due to the sustained and 
continuous release of PTX from PGC-PTX NPs over an extended period, potency is 
reduced relative to PTX-C/E151. Interestingly, both HMW PLGA blend formulations as 
well as the 1:19 PGC-PTX/LMW PLGA NPs demonstrate significantly enhanced potency 
relative to PGC-PTX NPs, as indicated by the reduced 50% inhibitory concentrations (IC50) 
(Table 4.1). PGC-PTX NPs have an IC50 of 59.4 ng/mL PTX. Meanwhile, the 1:4 and 1:19 
PGC-PTX/HMW PLGA NPs exhibit similarly reduced IC50s of 37.6 and 36.7 ng/mL PTX, 
respectively. However, 1:4 and 1:19 PGC-PTX/LMW PLGA NPs have IC50s of 60.4 and 
25.9 ng/mL PTX, respectively, with the 1:19 PGC-PTX/LMW PLGA NPs exhibiting the 
greatest cytotoxic effect among the NP formulations. A trend correlating potency with 
PLGA molecular weight or content is not observed. Nonetheless, the incorporation of 





 In summary, PGC-PTX/PLGA nanocarriers with enhanced in vitro efficacy are 
prepared and characterized. PGC-PTX and PGC-PTX/PLGA NPs exhibit similar sizes, 
PDIs, and zeta potentials. Although the polymer blend nanocarriers demonstrate 
significantly improved anticancer potency relative to PGC-PTX NPs, nanomechanical 
properties are not impacted by the addition of PLGA. Future studies are warranted to 
evaluate the mechanism by which PLGA improves nanocarrier efficacy. For example, the 
incorporation of PLGA may reduce core hydrophobicity and increase water permeability, 
resulting in increased rates of PTX release. Previously published reports demonstrate a 
robust correlation between in vitro drug carrier efficacy and release kinetics, with faster 
releasing formulations exhibiting greater potency151, 162, 185. The continued study and 
modulation of nanocarrier core composition and properties is a promising approach for the 
elucidation of essential design criteria in the development and translation of effective 
polymer therapeutics. 
 
4.4 Materials and Methods 
4.4.1 Nanoparticle Preparation 
 Poly(1,2-glycerol carbonate)-graft-succinic acid-paclitaxel with 43 mol% (64 wt%) 
paclitaxel (PTX) conjugation (i.e., PGC-PTX) was synthesized as previously described150, 
151. High molecular weight (HMW; 30,000-60,000 Da) and low molecular weight (LMW; 
7,000-17,000 Da) poly(D,L-lactide-co-glycolide) (PLGA) with a lactide:glycolide ratio of 




NPs were subsequently prepared by miniemulsion151. The core components, including 
PGC-PTX and/or PLGA, were added to 0.5 mL dichloromethane, and added to a 2 mL 
solution of sodium dodecyl sulfate (SDS) in pH 7.4 10 mM phosphate buffer at a 1:5 
SDS:polymer mass ratio. The mixture was then emulsified under an argon blanket using a 
Sonics Vibra-Cell VCX-600 Ultrasonic Processor (Sonics & Materials; Newtown, CT), 
and the resulting NP suspension was stirred under argon for 2 hours and under air overnight 
to allow for the evaporation of remaining solvent. The NPs were then dialyzed for 24 hours 
against 1 L of 5 mM pH 7.4 phosphate buffer. The dialysis buffer was exchanged with 
fresh buffer after 10 hours of dialysis.  
4.4.2 Nanoparticle Diameter, Polydispersity, and Zeta Potential 
 NP diameter, PDI, and zeta potential were determined using dynamic light 
scattering (DLS) via a Brookhaven 90Plus Particle Size Analyzer (Brookhaven Instruments 
Corporation; Holtsville, NY). NPs were diluted in DI water in order to achieve a count rate 
of approximately 150 kilocounts per second. Zeta potentials were measured using the 
Brookhaven Instruments Corporation ZetaPALS zeta potential analyzer via the 
Smoluchowski method. Data presented are the averages of number-weighted size 
distributions ± standard deviation of three independently prepared samples per NP 





4.4.3 Nanoparticle Visualization via Scanning Electron Microscopy  
 A Zeiss SUPRA 55VP field emission scanning electron microscope (FE-SEM) 
(Carl Zeiss Microscopy; Jena, Thuringia, Germany) was used to visualize NPs. Samples 
were prepared by diluting the NP suspension 1000x in DI water, and dropping a 10 μL 
aliquot on a silicon wafer. After samples were allowed to air-dry overnight, they were 
coated with Au/Pd using a Cressington 108 Manual Sputter Coater (Cressington Scientific 
Instruments; Watford, England, UK). 
4.4.4 Nanomechanical Characterization 
 Atomic force microscopy (AFM) was performed using a MFP-3D microscope 
(Asylum Research; Santa Barbara, CA). The contact mode was applied using a silicon 
nitride tip (MLCT, Bruker AFM Probes; Camarillo, CA) with a nominal spring constant of 
40 pN/nm and a diameter of 12 nm. Samples were prepared by diluting the suspensions 
100,000x in DI water, and dropping a 10 μL aliquot on a positively charged glass slide. 
NPs were immobilized by air drying. Prior to imaging, samples were rehydrated by adding 
a 20 μL drop of DI water. Force spectroscopy was obtained over a 250 nm extension length 
and a 500 nm/s approaching and retreating velocity. Force curves (N=100) were collected 
over an area of 500 x 500 nm2. The set-point was at 500 pN. We distinguished force curves 
resulting from a tip-particle interaction from those resulting from a tip-substrate interaction 
by height difference as well as the presence of extension peaks upon retraction. To 
determine the elastic or Young’s modulus, 𝐸, the Hertz’s model for non-adhesive elastic 










Here, 𝜈 is the Poisson ratio of the sample (set to 0.33 for a polymer), and 𝛼 is the half 
opening angle of the indenting tip (36°). All analysis was done using Igor Pro software 
(WaveMetrics Inc.; Portland, OR). Statistical analysis was performed with one-way 
ANOVA. 
4.4.5 Cell Culture 
 MDA-MB-231 cells were cultured in Dulbecco's Modified Eagle Medium 
(DMEM) supplemented with 10% fetal bovine serum (FBS) and 1% 
penicillin−streptomycin. Cells were maintained at 37°C with 5% CO2 in a humidified 
environment. 
4.4.6 In Vitro Cytotoxicity 
 MDA-MB-231 cells were seeded in 96-well plates at a density of 4000 cells/well, 
and allowed to adhere for 24 hours. On each plate, blank wells (media only) were defined 
as 0% viability, and wells with untreated cells were defined as 100% viability. Dilutions 
of PGC-PTX NPs, PGC-PTX/PLGA NPs, or PTX formulated in Cremophor EL/ethanol 
(1:1 v/v; PTX-C/E) were prepared, and cells were treated with 5000, 1000, 500, 100, 50, 
10, 5, 1, 0.5, or 0.1 ng/mL PTX for 5 days. The 3-(4,5-dimethylthiazol-2-yl)-5(3-
carboxymethonyphenol)-2-(4-sulfophenyl)-2H-tetrazolium (MTS) assay (CellTiter 96 
Aqueous One, Promega; Madison, WI) was used to assess cell viability. A Beckman 
Coulter AD 340 plate reader (Beckman Coulter Inc.; Brea, CA) was used to determine the 




media blanks and normalizing the absorbance of each well to the average absorbance of 
the untreated cells. The 50% inhibitory concentrations, or IC50 values, were determined by 
fitting the resultant data to sigmoidal four-parameter logistic curves using GraphPad Prism 
(GraphPad Software, Inc.; La Jolla, CA). Each curve represents the average ± standard 
deviation of three experiments in which n=6-8/treatment group. 
4.4.7 Statistics 
All data are reported as mean ± standard deviation. Differences between groups 
were evaluated using GraphPad Prism (GraphPad Software, Inc.; La Jolla, CA) via one-







Figure 4.1 Structure and formulation of PGC-PTX/PLGA NPs. (a) Structure of PGC-PTX 
conjugate. (b) PGC-PTX/PLGA NPs are formulated by emulsifying the mixture of the two 







Figure 4.2 Characterization of PGC-PTX/PLGA NPs. (a) DLS size measurements of PGC-
PTX NPs and PGC-PTX/PLGA NPs. (b) Polydispersity indices and (c) zeta potentials of 
NPs. Data is presented as the mean ± standard deviation of three independently formulated 







Figure 4.3 Scanning electron micrographs of (a) PGC-PTX NPs, (b) HMW PLGA NPs, 
(c) 1:4 PGC-PTX/HMW PLGA NPs, (d) 1:19 PGC-PTX/HMW PLGA NPs, (e) LMW 















Figure 4.5 PGC-PTX/PLGA NP in vitro cytotoxicity. MDA-MB-231 breast cancer cells 
were incubated with PTX-C/E or one of five NP formulations. Cell viability was evaluated 
after 5 days of exposure. All experiments were performed in triplicate, with data presented 





Table 4.1 In vitro IC50 of PTX-C/E, PGC-PTX NPs, and PGC-PTX/PLGA NPs after 5 







CHAPTER 5: Conclusions and Future Outlook 
 
 The conjugation of active agents to polymers is of significant clinical interest due 
to the numerous advantages conferred by macromolecular carriers. These programmable 
polymer therapeutics afford the clinically transformative ability to modulate 
pharmacokinetics, biodistribution, and bioavailability via the rational design of polymer-
drug conjugate physicochemical characteristics such as composition, architecture, size, and 
linker chemistry. In Chapter 1, central design considerations as well as recent advances in 
polymer-drug conjugate development are presented. Currently, the major classes of 
polymer-drug conjugates in the clinic or in clinical development are polymer-protein 
conjugates, polymer-small molecule drug conjugates, dendrimers, and polymeric 
nanoparticles. Polymeric nanoparticles are colloidal carriers that typically possess a core-
shell architecture, in which the hydrophobic polymer core is sequestered and stabilized by 
a hydrophilic corona. Like other macromolecular carriers, nanoparticles afford improved 
delivery of hydrophobic agents as well as altered pharmacokinetics and biodistribution. 
However, due to their solid nature, colloidal polymeric nanoassemblies uniquely sequester 
active agents in their hydrophobic core. Therefore, these carriers provide distinct 
advantages such as higher drug loading capacities as well as greater control of drug release 
kinetics. Nonetheless, despite significant strides in the field of macromolecular 
therapeutics, current polymer-drug conjugate nanoparticles are limited by low drug 
loadings, rapid drug release, and limited tunability of core properties. This dissertation 




nanocarrier that enables high, controlled paclitaxel (PTX) loadings, tunable and sustained 
drug release kinetics, and modulation of nanocarrier properties. Accordingly, poly(1,2-
glycerol carbonate)-graft-succinic acid-paclitaxel nanoparticles (PGC-PTX NPs) address 
a significant unmet clinical need for local and sustained chemotherapy in the treatment of 
peritoneal carcinomatosis.  
The synthesis of PGC-PTX as well as the preparation and characterization of PGC-
PTX NPs are described in Chapter 2. Poly(1,2-glycerol carbonate) (PGC) is a novel, 
biodegradable, and biocompatible polymer consisting of only glycerol and carbon dioxide. 
The polymer’s functionalizable pendant primary hydroxy enables high, controlled PTX 
loadings of up to 70 mol%, or 74 wt%. PGC-PTX NPs are prepared with a sodium dodecyl 
sulfate surface coating via emulsification. The resulting PGC-PTX nanocarriers exhibit 
high PTX concentrations >15 mg/mL, sub-100 nm diameters, narrow dispersity, and 
storage stability for up to 6 months. The sequestration of PTX in the hydrophobic 
nanoparticle core additionally impedes the penetration of water, enabling sustained and 
controlled drug release over an extended period of 70 days. PGC-PTX NPs are rapidly 
internalized and exhibit dose-dependent toxicity in cancer cells in vitro. In vivo, PGC-PTX 
NPs are safely administered at doses exceeding the median lethal dose of standard PTX. 
The utility of this system is demonstrated in preclinical models of peritoneal 
carcinomatosis, in which long-term regional chemotherapy improves patient outcomes but 
is limited by catheter-related complications. In murine models of peritoneal mesothelioma, 
a single high-dose of intraperitoneally (IP) administered PGC-PTX NPs confers an 




regimen. Therefore, PGC-PTX NPs afford the safe and facile implementation of sustained 
regional chemotherapy.  
The design of PGC-PTX NPs is further optimized in Chapter 3. Specifically, the 
compatibility between unconjugated PTX and conjugated PTX is harnessed to enable the 
physical entrapment of up to 50 wt% additional unconjugated drug. The resulting dual-
loaded nanocarriers (i.e., PGC-PTX + PTX NPs) maintain low dispersity, sub-100 nm 
diameters, and additionally afford unprecedented, ultra-high drug loadings >100 wt%. 
Additionally, the incorporation of physically entrapped PTX enables modulation of 
nanomechanical properties and PTX release kinetics. Despite the high loading of 
unconjugated PTX, PGC-PTX + PTX NPs do not exhibit any burst release effects, but 
release PTX continuously over 15 days. Importantly, in contrast to PGC-PTX NPs, PGC-
PTX + PTX NPs enable the simultaneous optimization of drug loading and in vitro potency. 
PGC-PTX + PTX NPs are safely administered at high doses in vivo, and additionally afford 
significantly improved survival relative to weekly, multi-dose PTX treatment in a murine 
model of peritoneal mesothelioma. Therefore, the tunability of these dual-loaded carriers 
provides an opportunity to optimize nanoparticle-mediated drug delivery.  
Modulation of nanoparticle core composition is explored in Chapter 4. 
Biodegradable and biocompatible poly(lactide-co-glycolide) (PLGA) is incorporated with 
PGC-PTX to form PGC-PTX/PLGA polymer blend nanocarriers. The incorporation of an 
additional polymer in the nanocarrier core can disrupt intermolecular forces between the 
polymer chains and reduce compact polymer aggregation. Therefore, this approach can be 




Although the incorporation of PLGA does not significantly alter nanocarrier stiffness, 
PGC-PTX/PLGA NPs exhibit improved in vitro potency relative to PGC-PTX NPs. 
Further studies are needed to elucidate the mechanism by which PLGA enhances 
nanocarrier efficacy.  
The work presented herein provides significant opportunities for further 
development. For example, evaluation of PGC-PTX NP biodistribution, pharmacokinetics, 
and in vivo drug release kinetics can contribute to the rational design and optimization of 
second-generation PGC-PTX NPs. Additionally, alternative design implementations can 
build upon this work. For example, drug release can be modulated through the 
incorporation of stimuli-sensitive linking chemistries. Furthermore, the high functionality 
and biodegradability of PGC renders it an ideal drug carrier, warranting the conjugation of 
other therapeutic entities.  
In summary, this dissertation describes the design, development, and 
characterization of a novel polycarbonate-paclitaxel conjugate nanocarrier for tunable and 
sustained drug delivery. The continued design and implementation of novel, programmable 
macromolecular therapeutics will facilitate the realization of enhanced treatment 
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